{"meta":{"query_hash":"5eb94abd487e","filters":{"venue":"Journal of Hematology & Oncology"},"cohort_total":63,"direct_labels_cover":0,"predictions_cover":63,"exported":63,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5eb94abd487e","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Hematology+%26+Oncology"},"results":[{"id":"W2000221743","doi":"10.1186/1756-8722-1-8","title":"Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)","year":2008,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Coleman Foundation","keywords":"Myeloid leukemia; Leukemia; Myeloid; Cancer research; Biology; Phage display; Peptide library; Biopanning; Immunology; Antibody; Biochemistry; Peptide sequence","score_opus":0.028845974154937348,"score_gpt":0.2923246518097474,"score_spread":0.2634786776548101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000221743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872765,0.002462163,0.0076674353,0.00021383289,0.000032188178,0.00023700426,0.0005555307,0.000062927276,0.0014924676],"genre_scores_gemma":[0.98197466,0.0011696983,0.012307685,0.0003415114,0.000077952114,0.00013708527,0.0021959022,0.00002347179,0.0017720191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982685,0.000031657477,0.000015053722,0.000038711125,0.000053440872,0.000034377597],"domain_scores_gemma":[0.9998361,0.000060101334,0.000025152116,0.000013657009,0.000024576146,0.000040418912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018861967,0.00036549574,0.00035725234,0.00027838745,0.00016021382,0.0004416769,0.00017231506,0.00034429083,0.0019545318],"category_scores_gemma":[0.0003991018,0.00011503183,0.00020546188,0.00025444516,0.00013185375,0.00012884448,0.0002835966,0.0005365425,0.00071325205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036775976,0.00015321415,0.008845611,0.00012833413,0.00002359675,0.00047203546,0.000065044514,0.00031335437,0.9619607,0.00010572336,0.00037836123,0.027186275],"study_design_scores_gemma":[0.0003453852,0.0038519758,0.054645896,0.000048926904,0.00013469157,0.010617176,0.00015920054,0.0029257552,0.90956116,0.000280754,0.017407017,0.000022062213],"about_ca_topic_score_codex":0.00012679795,"about_ca_topic_score_gemma":0.0002320315,"teacher_disagreement_score":0.0019545318,"about_ca_system_score_codex":0.00014678162,"about_ca_system_score_gemma":0.00022874886,"threshold_uncertainty_score":0.0065385103},"labels":[],"label_agreement":null},{"id":"W2098128741","doi":"10.1186/1756-8722-7-21","title":"Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; Erg; Immunohistochemistry; Internal medicine; Biochemical recurrence; Medicine; Cohort; Prostate; Cancer; Oncology; Cancer research; Pathology; Biology; Prostatectomy; Signal transduction; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.011443042562657504,"score_gpt":0.3113333247399142,"score_spread":0.2998902821772567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098128741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988017,0.000641781,0.00016763236,0.000020179566,0.0000020869106,0.0000025579948,0.00015557563,0.0000048814627,0.00020349315],"genre_scores_gemma":[0.9991887,0.00022894982,0.00013274264,0.00000899027,0.000002621705,0.0000017748414,0.00029025527,0.0000017209294,0.00014424983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998728,0.000017642034,0.000013239459,0.000030097586,0.000043744312,0.000022435845],"domain_scores_gemma":[0.9996942,0.000046826975,0.00015198992,0.00001929466,0.00004173513,0.000046028108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025637232,0.00021936277,0.00024745383,0.0005278783,0.00024480748,0.0004686545,0.00017909404,0.0002755609,0.00084060535],"category_scores_gemma":[0.0004363687,0.00009285611,0.00032491778,0.00066217314,0.00025556062,0.00015530206,0.0004086313,0.00025362967,0.0001604699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013164154,0.000031212625,0.9141169,0.00011019635,0.00016901374,0.0010797626,0.00014056594,0.00044100237,0.07073552,0.00014254186,0.00017493298,0.011541933],"study_design_scores_gemma":[0.0000074654495,0.00012548498,0.9902333,0.000008049136,0.00006982266,0.003225259,0.00013223692,0.00035131446,0.0051157963,0.00015089332,0.0005734657,0.0000069905836],"about_ca_topic_score_codex":0.0017250609,"about_ca_topic_score_gemma":0.0021108896,"teacher_disagreement_score":0.0017250609,"about_ca_system_score_codex":0.00020351195,"about_ca_system_score_gemma":0.00023471384,"threshold_uncertainty_score":0.0034300685},"labels":[],"label_agreement":null},{"id":"W2104096033","doi":"10.1186/1756-8722-3-13","title":"Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Mass spectrometry; Hematology; Malignancy; Computational biology; Proteomics; Biomarker discovery; Disease; Internal medicine; Oncology; Bioinformatics; Cancer research; Biology; Chemistry; Biochemistry; Chromatography; Gene","score_opus":0.06230023267059034,"score_gpt":0.4045304902953145,"score_spread":0.3422302576247242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104096033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044510647,0.995513,0.0014199695,0.000677507,0.00023014628,0.000010721128,0.000022545231,0.00001944069,0.0016615775],"genre_scores_gemma":[0.0019377102,0.9931988,0.0030773068,0.0004290174,0.0003090621,0.000014222131,0.00003733314,0.0000029999894,0.0009934786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964905,0.00006580474,0.000033786717,0.000054875058,0.00017385722,0.000022613178],"domain_scores_gemma":[0.9996166,0.00015762345,0.000050361657,0.000015330259,0.0001261222,0.000033900975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092091365,0.000979619,0.0016324128,0.0024837765,0.00031851538,0.0010433263,0.00087710714,0.0017146709,0.001569797],"category_scores_gemma":[0.0007581247,0.00042782284,0.0005498745,0.0023439093,0.00065975514,0.0020869512,0.0006906728,0.0020263812,0.0027670548],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000967567,0.00018039231,0.00061654847,0.012268982,0.0001823576,0.0008718383,0.00012163227,0.0006508455,0.038243804,0.00667198,0.021034792,0.91906],"study_design_scores_gemma":[0.000028478493,0.00019340643,0.0024421972,0.0016488842,0.00013148319,0.0053119683,0.00013843639,0.000604177,0.014203714,0.0065952507,0.96864253,0.000059404563],"about_ca_topic_score_codex":0.00072497124,"about_ca_topic_score_gemma":0.001049363,"teacher_disagreement_score":0.0024837765,"about_ca_system_score_codex":0.0008158385,"about_ca_system_score_gemma":0.0008571481,"threshold_uncertainty_score":0.0059193373},"labels":[],"label_agreement":null},{"id":"W2112825380","doi":"10.1186/1756-8722-6-26","title":"Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"Cancer Research Society","keywords":"Telomere; Myeloid leukemia; Hematology; Leukemia; Medicine; Biology; Cancer research; Internal medicine; Genetics; DNA","score_opus":0.01536367648813868,"score_gpt":0.2740955660179467,"score_spread":0.258731889529808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112825380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976496,0.0009866934,0.00040088306,0.000017353519,0.000005341945,0.000014044439,0.00039112652,0.000021769469,0.0005130704],"genre_scores_gemma":[0.9984555,0.00029667476,0.0003077237,0.000015131053,0.000005421515,0.000017674616,0.00057169824,0.0000024860378,0.0003275595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999026,0.0000093368535,0.000010538311,0.000022557218,0.000026233969,0.00002880268],"domain_scores_gemma":[0.99982905,0.000030264298,0.00004051375,0.000023935369,0.000038276343,0.00003789035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014305102,0.00014825858,0.0001957137,0.00045050064,0.00023168398,0.00019881656,0.00008216843,0.00016193104,0.0017068181],"category_scores_gemma":[0.00015140169,0.00010539157,0.00010641131,0.000356589,0.00015229084,0.00009986782,0.00016284382,0.00017311642,0.0003142297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005380447,0.000038956263,0.039364934,0.00009282492,0.000017136383,0.0005423981,0.00010288579,0.00006409047,0.9560334,0.000069268855,0.00010000327,0.0030361458],"study_design_scores_gemma":[0.00006984014,0.001056067,0.68606085,0.000012530596,0.00008069521,0.0062422385,0.00019145208,0.00047656856,0.30159718,0.000101093014,0.0041012955,0.00001021535],"about_ca_topic_score_codex":0.00068741664,"about_ca_topic_score_gemma":0.00094262365,"teacher_disagreement_score":0.0017068181,"about_ca_system_score_codex":0.0002269897,"about_ca_system_score_gemma":0.0001728746,"threshold_uncertainty_score":0.005709827},"labels":[],"label_agreement":null},{"id":"W2123870670","doi":"10.1186/1756-8722-6-84","title":"Enhancing bone marrow regeneration by SALL4 protein","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; New York State Stem Cell Science","keywords":"Haematopoiesis; Stem cell; Cord blood; Bone marrow; Transplantation; Progenitor cell; Immunology; Cancer research; Biology; Hematology; Regeneration (biology); Medicine; Internal medicine; Cell biology","score_opus":0.004374882000059221,"score_gpt":0.24074081394738667,"score_spread":0.23636593194732744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123870670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894282,0.0019677565,0.0063880114,0.00022401861,0.000043525968,0.000052418338,0.00037379816,0.00022754923,0.0012946912],"genre_scores_gemma":[0.9905813,0.0009381679,0.0048916605,0.00011141142,0.000014706496,0.000044469743,0.00074740686,0.000032607477,0.00263822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990666,0.000023126158,0.000006436341,0.000014688333,0.000023805642,0.00002523934],"domain_scores_gemma":[0.9999447,0.000008257083,0.000017043525,0.000005832916,0.000005992473,0.000018176821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016203252,0.00033146408,0.00016543164,0.00025535043,0.00011795327,0.00020961792,0.00020546287,0.00025521853,0.0017464461],"category_scores_gemma":[0.00007086563,0.00010899894,0.0002676637,0.00012792167,0.00022358962,0.00013412464,0.00026198768,0.00047781947,0.00048561732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006191383,0.000026593025,0.00006282014,0.00002917763,0.0000035271567,0.000015433649,0.0000058733467,0.00005257541,0.99881244,0.00005351368,0.000035072175,0.00084107503],"study_design_scores_gemma":[0.000023082808,0.00032633057,0.00088503596,0.000004384056,0.000016684422,0.000080354366,0.00000881543,0.0004951856,0.99589974,0.0000308185,0.0022269904,0.0000025408976],"about_ca_topic_score_codex":0.0004019994,"about_ca_topic_score_gemma":0.00058695837,"teacher_disagreement_score":0.0017464461,"about_ca_system_score_codex":0.00024562227,"about_ca_system_score_gemma":0.00022942072,"threshold_uncertainty_score":0.0058424473},"labels":[],"label_agreement":null},{"id":"W2133654917","doi":"10.1186/1756-8722-6-46","title":"A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Sorafenib; Rash; Diffuse large B-cell lymphoma; Hematology; Lymphoma; Oncology; Progression-free survival; Neutropenia; Overall survival; Gastroenterology; Chemotherapy; Hepatocellular carcinoma","score_opus":0.028262361654969093,"score_gpt":0.35753368450433876,"score_spread":0.32927132284936966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133654917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972662,0.0006258657,0.0002982157,0.0001322629,0.000022752953,0.0009805836,0.0002708948,0.000024360845,0.00037895885],"genre_scores_gemma":[0.99209905,0.0011925078,0.0019096617,0.00040182783,0.000094457515,0.0016000972,0.0016358779,0.000017751867,0.0010487755],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991887,0.0005301564,0.00003400605,0.00008188361,0.00006737939,0.00009790255],"domain_scores_gemma":[0.999081,0.00013253505,0.0001357922,0.000074775264,0.00005113952,0.0005247538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034290382,0.0012547242,0.0018383879,0.00037406245,0.00033624138,0.00058963575,0.0007112751,0.0007930298,0.0013870416],"category_scores_gemma":[0.0009053546,0.0005822248,0.00097313244,0.00042222426,0.0008340513,0.0005037755,0.00034063548,0.0020147793,0.00040594084],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5956615,0.1307027,0.03779481,0.00081973814,0.0026861127,0.00083760417,0.0007380462,0.0042993664,0.09665289,0.00030767694,0.0036920265,0.12580755],"study_design_scores_gemma":[0.529276,0.42829224,0.033368595,0.000017263885,0.00062600174,0.00044199402,0.000075712094,0.001312472,0.004314225,0.0001306208,0.0021154496,0.000029401608],"about_ca_topic_score_codex":0.0010227219,"about_ca_topic_score_gemma":0.0024231556,"teacher_disagreement_score":0.0034290382,"about_ca_system_score_codex":0.00058364635,"about_ca_system_score_gemma":0.001469876,"threshold_uncertainty_score":0.018134713},"labels":[],"label_agreement":null},{"id":"W2137990944","doi":"10.1186/1756-8722-3-8","title":"From basic research to clinical development of MEK1/2 inhibitors for cancer therapy","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Cancer research; Regulator; Cancer; Kinase; Receptor tyrosine kinase; MAPK/ERK pathway; Hematology; Tyrosine kinase; Signal transduction; Function (biology); Hyperactivation; Medicine; Biology; Internal medicine; Cell biology; Gene; Biochemistry","score_opus":0.23335411210150298,"score_gpt":0.5308665528212848,"score_spread":0.29751244071978183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137990944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044982668,0.99350923,0.00083188503,0.0013256556,0.00038621738,0.00002323323,0.000030685067,0.00003067518,0.0034126008],"genre_scores_gemma":[0.0021255885,0.99402505,0.0009546238,0.0007599545,0.00040653232,0.000027747099,0.000043488766,0.0000050566264,0.0016519687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977773,0.000046802536,0.000026789276,0.000038714912,0.000083732346,0.000026102776],"domain_scores_gemma":[0.999726,0.00010787256,0.00003426426,0.00001342856,0.00007500208,0.000043373355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010493726,0.0009451835,0.0012636537,0.0017012439,0.00028132563,0.0011160792,0.00094657455,0.0013416314,0.004546742],"category_scores_gemma":[0.0006772407,0.00038500456,0.00045053175,0.0012159529,0.00081296795,0.0014620731,0.00067895226,0.0029055204,0.0039604283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015034396,0.00019627894,0.00014745614,0.0057681943,0.00005409776,0.0004109926,0.000060227372,0.00054437964,0.007499758,0.0069809332,0.032861717,0.94532555],"study_design_scores_gemma":[0.00007705846,0.00023355971,0.0006099435,0.0014217849,0.000052064293,0.0015866028,0.000029455683,0.00017882831,0.0024345343,0.0033622547,0.9899961,0.00001784517],"about_ca_topic_score_codex":0.00054612494,"about_ca_topic_score_gemma":0.0011022823,"teacher_disagreement_score":0.004546742,"about_ca_system_score_codex":0.0010466529,"about_ca_system_score_gemma":0.001000258,"threshold_uncertainty_score":0.0152103305},"labels":[],"label_agreement":null},{"id":"W2139585567","doi":"10.1186/1756-8722-6-17","title":"A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Prasugrel; Medicine; Placebo; Thienopyridine; Internal medicine; Clinical endpoint; P2Y12; Randomized controlled trial; Gastroenterology; Clopidogrel; Myocardial infarction; Pathology","score_opus":0.012846710098927794,"score_gpt":0.30613434439156234,"score_spread":0.29328763429263455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139585567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738013,0.005323938,0.0017825766,0.0010203986,0.0013999025,0.013436841,0.0013299212,0.00021885925,0.0016862198],"genre_scores_gemma":[0.96023023,0.0040420657,0.004561312,0.002286862,0.0013816379,0.022964975,0.0012412732,0.000046154575,0.0032453726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988422,0.0006119057,0.00008950095,0.00022882283,0.000090767106,0.00013683547],"domain_scores_gemma":[0.9986002,0.00038343386,0.0003516564,0.00012035448,0.0001421833,0.00040219046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030247949,0.002199774,0.004880547,0.0006079186,0.0006690768,0.0011775515,0.0009253527,0.00222225,0.007805697],"category_scores_gemma":[0.0029026375,0.0011312201,0.0017466655,0.00051335106,0.0015447557,0.0014753353,0.00049494044,0.0028195812,0.0011479225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9845404,0.0075519006,0.00020585397,0.00035445153,0.00040379332,0.000021425574,0.000032580367,0.00011226391,0.0017555588,0.000048114718,0.0003037622,0.0046699587],"study_design_scores_gemma":[0.957149,0.041833267,0.00044771485,0.000009421267,0.00013119857,0.000010549678,0.0000066303146,0.00010968784,0.00010279074,0.000040167724,0.00015373154,0.0000058124115],"about_ca_topic_score_codex":0.0005109549,"about_ca_topic_score_gemma":0.00103813,"teacher_disagreement_score":0.007805697,"about_ca_system_score_codex":0.0005797584,"about_ca_system_score_gemma":0.0016369942,"threshold_uncertainty_score":0.026112676},"labels":[],"label_agreement":null},{"id":"W2143090141","doi":"10.1186/1756-8722-6-63","title":"High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Haemophilia; Internal medicine; Cohort; Retrospective cohort study; Hematology; Surgery","score_opus":0.022850582862280533,"score_gpt":0.293730886017961,"score_spread":0.27088030315568046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143090141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99959093,0.00010856562,0.000052777206,0.000012048566,0.0000026604982,0.0000046580403,0.00012082459,0.0000017506009,0.00010577343],"genre_scores_gemma":[0.9995704,0.000049755967,0.000035828278,0.000010539976,0.000007235865,0.0000065252493,0.00024906042,0.0000017897419,0.000068706206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881446,0.00028491963,0.00012957261,0.0003800108,0.00022527653,0.00016581001],"domain_scores_gemma":[0.99612314,0.0006730983,0.0019844023,0.0004647387,0.00024895038,0.00050578057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001034418,0.00029151898,0.0006766114,0.00079279364,0.00074831565,0.0010800426,0.00042214675,0.00047422847,0.00126375],"category_scores_gemma":[0.0033772576,0.00040492765,0.0004666505,0.0008802468,0.00039931454,0.00061791786,0.00056122325,0.00059887534,0.00027749865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015347713,0.000029656072,0.99869776,0.000004442791,0.000032993372,0.0001723363,0.00010037639,0.000015781976,0.00020402185,0.0000075352614,0.000037641865,0.00054403057],"study_design_scores_gemma":[0.000015114708,0.00025698027,0.9981001,0.00000350298,0.000030410702,0.0011107463,0.00012472038,0.00013247819,0.000080052865,0.000010944773,0.00012953255,0.0000054235716],"about_ca_topic_score_codex":0.0027760628,"about_ca_topic_score_gemma":0.0018710099,"teacher_disagreement_score":0.0027760628,"about_ca_system_score_codex":0.00039624094,"about_ca_system_score_gemma":0.0003784827,"threshold_uncertainty_score":0.005519867},"labels":[],"label_agreement":null},{"id":"W2145273779","doi":"10.1186/1756-8722-5-s1-a7","title":"Targeting p53 by small molecule p53 activators in multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Mdm2; Cancer research; Cell cycle checkpoint; Chronic lymphocytic leukemia; Ubiquitin ligase; Multiple myeloma; Leukemia; Apoptosis; Cell cycle; Myeloid leukemia; Medicine; Biology; Cancer; Ubiquitin; Immunology; Internal medicine; Gene","score_opus":0.019457618634709878,"score_gpt":0.28950177208906747,"score_spread":0.2700441534543576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145273779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5709185,0.37228924,0.02567136,0.003920902,0.0012555487,0.0008592593,0.001402596,0.0014899966,0.022192705],"genre_scores_gemma":[0.8492203,0.13143392,0.009198136,0.001005146,0.00030204325,0.00031841095,0.0009558379,0.000072703966,0.007493473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991786,0.000009631987,0.0000047722556,0.000017213504,0.000030980085,0.000019550915],"domain_scores_gemma":[0.99997187,0.0000047981976,0.0000075964317,0.0000023873301,0.000004553126,0.000008806438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018276158,0.00038861495,0.00045138766,0.00051682646,0.00017963465,0.00036763193,0.0004063106,0.000437515,0.0020696367],"category_scores_gemma":[0.0000997247,0.00016741791,0.00034018295,0.0004627738,0.00018172401,0.00030722216,0.00030867572,0.0011835216,0.00063834613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010995138,0.00070125563,0.00041076427,0.0007409272,0.00007095654,0.00046375324,0.00005954224,0.00094975845,0.9039074,0.001475429,0.0035922627,0.08652838],"study_design_scores_gemma":[0.0013236185,0.007319184,0.005569664,0.0001774153,0.00029918525,0.0027970276,0.000050253286,0.0034098513,0.8090289,0.0013491022,0.16863777,0.000038048456],"about_ca_topic_score_codex":0.0004975131,"about_ca_topic_score_gemma":0.001142855,"teacher_disagreement_score":0.0020696367,"about_ca_system_score_codex":0.0005669973,"about_ca_system_score_gemma":0.00017736336,"threshold_uncertainty_score":0.0069235563},"labels":[],"label_agreement":null},{"id":"W2147881986","doi":"10.1186/1756-8722-5-67","title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Takeda Oncology; European Society for Medical Oncology; National Comprehensive Cancer Network","keywords":"Rituximab; Medicine; Bortezomib; Internal medicine; Follicular lymphoma; International Prognostic Index; Hazard ratio; Lymphoma; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Confidence interval; Multiple myeloma","score_opus":0.015188422910360717,"score_gpt":0.31005445830081385,"score_spread":0.29486603539045314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147881986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96006584,0.030509587,0.0013915368,0.0009830251,0.00085663697,0.0033608044,0.0012354427,0.00013630484,0.0014608048],"genre_scores_gemma":[0.9908931,0.003011385,0.0008318337,0.0008420293,0.0003675147,0.002532085,0.000833646,0.00002337066,0.00066505675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968935,0.0019834395,0.0003793284,0.0003519585,0.00014092181,0.00025080115],"domain_scores_gemma":[0.99757785,0.0010053596,0.0006787514,0.00029080058,0.00013313084,0.00031410792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005537706,0.0020687014,0.0056456067,0.0006368433,0.00044150435,0.0016718562,0.0010966021,0.0016312902,0.0036510485],"category_scores_gemma":[0.0059931786,0.0006764615,0.00929414,0.0007723604,0.00072993065,0.0009553605,0.00068244565,0.0019804114,0.00043981674],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969495,0.0006129061,0.0025177114,0.00092805864,0.0180722,0.00006286401,0.0000509455,0.00044291545,0.0008416308,0.000059638398,0.00039214324,0.006524004],"study_design_scores_gemma":[0.949195,0.022431057,0.0070574842,0.00014223022,0.018476458,0.00008469667,0.00007098341,0.0011193964,0.00027886097,0.00054229266,0.00056782184,0.00003360904],"about_ca_topic_score_codex":0.0012244775,"about_ca_topic_score_gemma":0.002915937,"teacher_disagreement_score":0.0056456067,"about_ca_system_score_codex":0.0012895475,"about_ca_system_score_gemma":0.0014559687,"threshold_uncertainty_score":0.029286504},"labels":[],"label_agreement":null},{"id":"W2148565111","doi":"10.1186/1756-8722-4-37","title":"Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","year":2011,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Peking Union Medical College; National Natural Science Foundation of China","keywords":"Stromal cell; Transfection; microRNA; Bone marrow; Cancer research; Hematology; Multiple myeloma; Cytotoxic T cell; Cell growth; Interleukin; Cell culture; Medicine; Biology; Immunology; Molecular biology; In vitro; Cytokine; Gene; Biochemistry","score_opus":0.022857659148931384,"score_gpt":0.3252212007589212,"score_spread":0.3023635416099898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148565111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7340155,0.02538355,0.006010299,0.19375892,0.0064616404,0.00033143532,0.00038857543,0.0006671111,0.032983005],"genre_scores_gemma":[0.91496813,0.011092605,0.004865855,0.041040998,0.0051251026,0.00019733589,0.00024958895,0.000039759918,0.02242061],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997048,0.000100505305,0.00004680849,0.000032915486,0.00007668306,0.000038299484],"domain_scores_gemma":[0.9996717,0.00017207993,0.000043910877,0.000028908238,0.000049786784,0.00003370034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003202067,0.00026125484,0.000483613,0.00016528358,0.0003226613,0.00047712607,0.00018227274,0.0019190209,0.0012696317],"category_scores_gemma":[0.0008857357,0.00013994506,0.00025163646,0.00016513882,0.00034264295,0.00031176518,0.00017926353,0.0016139746,0.00087340135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038972066,0.00081271946,0.03628192,0.0010022828,0.00012295379,0.17884865,0.0009769492,0.00085140433,0.46629563,0.005575784,0.106223956,0.19911064],"study_design_scores_gemma":[0.0009138133,0.002512607,0.0346286,0.00013980702,0.00017512625,0.3123646,0.0005421196,0.008330149,0.21589348,0.004846811,0.41956478,0.000088045024],"about_ca_topic_score_codex":0.00020707143,"about_ca_topic_score_gemma":0.0003910815,"teacher_disagreement_score":0.0019190209,"about_ca_system_score_codex":0.0005589968,"about_ca_system_score_gemma":0.00019309235,"threshold_uncertainty_score":0.0042473674},"labels":[],"label_agreement":null},{"id":"W2150291652","doi":"10.1186/1756-8722-2-28","title":"RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression","year":2009,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"Cancer research; Biology; Population; Medicine","score_opus":0.00950987039396989,"score_gpt":0.3002109589257798,"score_spread":0.2907010885318099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150291652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999155,0.0049108905,0.0023075487,0.00012296472,0.00001487366,0.000036958856,0.000892629,0.00016402513,0.0015586251],"genre_scores_gemma":[0.99309546,0.001526739,0.0017562665,0.000041421194,0.000012446806,0.000032586522,0.00144787,0.000018681467,0.0020685343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993026,0.0000061065853,0.0000048106112,0.000017837949,0.000025300063,0.00001572606],"domain_scores_gemma":[0.9998828,0.000016249387,0.00005649935,0.000006566887,0.000015508469,0.000022355593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010100812,0.00026496616,0.00021869449,0.00037375643,0.00013520314,0.00022431434,0.00020268177,0.0001907175,0.0014508906],"category_scores_gemma":[0.00017125168,0.000096058255,0.00011371936,0.00023682982,0.00014650321,0.00011717739,0.00011990929,0.00024692778,0.0005612286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013695337,0.000013132417,0.0026775827,0.000039940325,0.0000052174214,0.00012309013,0.000016511862,0.000065383894,0.992222,0.00011271442,0.00010711934,0.004480388],"study_design_scores_gemma":[0.00002935253,0.000317259,0.06751541,0.0000132811165,0.000044535347,0.0027966357,0.000046069625,0.0009775405,0.9186259,0.00014511701,0.009482345,0.000006543229],"about_ca_topic_score_codex":0.00036851325,"about_ca_topic_score_gemma":0.00035812444,"teacher_disagreement_score":0.0014508906,"about_ca_system_score_codex":0.0004389349,"about_ca_system_score_gemma":0.00016413412,"threshold_uncertainty_score":0.0048537254},"labels":[],"label_agreement":null},{"id":"W2152127926","doi":"10.1186/1756-8722-7-1","title":"Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; National Cancer Institute; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Docetaxel; Carboplatin; Rash; Internal medicine; Paclitaxel; Erlotinib; Nausea; Febrile neutropenia; Pharmacology; Oncology; Neutropenia; Chemotherapy; Cisplatin; Cancer; Epidermal growth factor receptor","score_opus":0.01163486206297069,"score_gpt":0.31655276048701236,"score_spread":0.30491789842404166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152127926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996043,0.002617602,0.00045500684,0.00079080847,0.00017732047,0.002856567,0.00113639,0.00013408436,0.0018716509],"genre_scores_gemma":[0.98601776,0.002407295,0.0017189722,0.0009270701,0.0002387607,0.0030810907,0.0025372365,0.00003833927,0.0030335267],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997322,0.000113898815,0.000012962805,0.00005257306,0.000024935756,0.00006340705],"domain_scores_gemma":[0.99942493,0.0000943641,0.00013051798,0.000031573185,0.000033780307,0.00028489376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013597277,0.0021914032,0.002226211,0.00044622965,0.0005048809,0.00091851427,0.00096789066,0.0010853647,0.0042115166],"category_scores_gemma":[0.00076570775,0.0007495461,0.001171794,0.00045096272,0.00091076817,0.0007970876,0.00035926726,0.0038441739,0.00096281455],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78708214,0.07570429,0.0056152507,0.0014309312,0.0012535276,0.000397084,0.00032140978,0.004408869,0.030913051,0.00034311,0.009298106,0.08323221],"study_design_scores_gemma":[0.7318446,0.25542727,0.0057890518,0.000039334984,0.00033188023,0.00025080654,0.0000363214,0.0015149007,0.0026291683,0.00021438631,0.0018997797,0.000022461012],"about_ca_topic_score_codex":0.0013564535,"about_ca_topic_score_gemma":0.0038525646,"teacher_disagreement_score":0.0042115166,"about_ca_system_score_codex":0.0012190151,"about_ca_system_score_gemma":0.002309539,"threshold_uncertainty_score":0.014088929},"labels":[],"label_agreement":null},{"id":"W2161274278","doi":"10.1186/1756-8722-6-23","title":"Targeting p53 by small molecules in hematological malignancies","year":2013,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital","funders":"Leukemia and Lymphoma Society","keywords":"Hematology; Hematologic Neoplasms; Medicine; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.04812151298779321,"score_gpt":0.3468081397408627,"score_spread":0.2986866267530695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161274278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037953013,0.99803823,0.00022236462,0.00014054366,0.00014709335,0.000007818826,0.000013980366,0.000011022874,0.0010394108],"genre_scores_gemma":[0.001198292,0.99759835,0.00027131263,0.00011830547,0.000114251015,0.000009400672,0.000029965042,0.0000015668385,0.0006585049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998996,0.000013968675,0.000012709093,0.000017119644,0.00004576642,0.000010762897],"domain_scores_gemma":[0.99988353,0.000049341954,0.000018545843,0.0000040597665,0.000029823897,0.00001461231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003109806,0.0006540555,0.0009921055,0.001998869,0.00023364632,0.00046035156,0.0005822953,0.00074454676,0.0024897144],"category_scores_gemma":[0.00031606155,0.00023420034,0.00043542444,0.0015784408,0.0003177562,0.00073722866,0.00046572307,0.0012960198,0.0018157328],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008565906,0.00011918152,0.00019743877,0.012059008,0.000071661045,0.00036008516,0.000051964067,0.00041304584,0.0075606555,0.002038976,0.016406178,0.96063626],"study_design_scores_gemma":[0.000036703746,0.0002091491,0.0012464204,0.0016581172,0.00013213078,0.0027208696,0.00004322919,0.00016452192,0.0026269688,0.0014644491,0.9896763,0.000021095386],"about_ca_topic_score_codex":0.0005461932,"about_ca_topic_score_gemma":0.0010763161,"teacher_disagreement_score":0.0024897144,"about_ca_system_score_codex":0.00037879965,"about_ca_system_score_gemma":0.00043072872,"threshold_uncertainty_score":0.008328915},"labels":[],"label_agreement":null},{"id":"W2162251295","doi":"10.1186/1756-8722-1-20","title":"First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting","year":2008,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical Oncology; Medicine; Survivin; Hematology; Internal medicine; Oncology; Clinical trial; Cancer","score_opus":0.045818258317923,"score_gpt":0.3651020862418146,"score_spread":0.3192838279238916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162251295","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19651355,0.73943216,0.0068617677,0.02505294,0.007570321,0.0015373926,0.00461273,0.0005757716,0.017843397],"genre_scores_gemma":[0.44484204,0.4633261,0.013181521,0.023631927,0.008791426,0.0014880139,0.014763441,0.00047826723,0.029497188],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99950147,0.00016176062,0.000050686762,0.000046995585,0.00011106888,0.00012802337],"domain_scores_gemma":[0.9987833,0.00035647216,0.00023938184,0.000047927024,0.00021528889,0.00035755296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031342471,0.0011895938,0.0016876278,0.00036041066,0.0003631837,0.0019123291,0.00059828203,0.0013949376,0.004020446],"category_scores_gemma":[0.0016117494,0.00030528576,0.0010165815,0.00042856252,0.00033190424,0.0012063467,0.0004476912,0.00324872,0.0014366761],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0129338,0.004188869,0.0030414336,0.0027478074,0.00068525784,0.00035094836,0.00017642451,0.00134041,0.043809086,0.0011287217,0.1127616,0.8168356],"study_design_scores_gemma":[0.024157263,0.13421541,0.023410834,0.0012576402,0.0031360001,0.004524623,0.00028889303,0.001770033,0.10541489,0.0020005237,0.6996673,0.00015666966],"about_ca_topic_score_codex":0.00033649278,"about_ca_topic_score_gemma":0.0016314829,"teacher_disagreement_score":0.004020446,"about_ca_system_score_codex":0.0009884452,"about_ca_system_score_gemma":0.0011398765,"threshold_uncertainty_score":0.016575694},"labels":[],"label_agreement":null},{"id":"W2168535495","doi":"10.1186/1756-8722-4-38","title":"Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4","year":2011,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; University of Nevada, Las Vegas","keywords":"Stem cell; Haematopoiesis; Progenitor cell; Hematology; Hematopoietic stem cell; Biology; Cancer research; Internal medicine; Cell biology; Medicine","score_opus":0.008481752249099743,"score_gpt":0.2282313107589216,"score_spread":0.21974955850982186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168535495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461174,0.0007646346,0.0030659123,0.000058476442,0.000018663155,0.000019998599,0.00036443365,0.00013074197,0.0009653285],"genre_scores_gemma":[0.99434185,0.00036801313,0.0022589108,0.000039426774,0.000008242238,0.000029875087,0.0007481951,0.0000321911,0.002173174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999051,0.00001672796,0.000010446479,0.000014311855,0.00003270416,0.000020720297],"domain_scores_gemma":[0.9999013,0.000013880868,0.000039625735,0.000011092618,0.000010142374,0.000024067414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014639665,0.00034273314,0.00013895535,0.00029265686,0.000100760786,0.0002351959,0.0002061876,0.00018257505,0.0015953599],"category_scores_gemma":[0.00008300297,0.00009473703,0.0002236536,0.00012457803,0.0002613587,0.00016061074,0.00027666363,0.00035240786,0.00036998306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042849977,0.00000868984,0.00017523092,0.000022103033,0.0000024644514,0.00002035528,0.000005465602,0.00004229522,0.9990036,0.000050245548,0.000018662977,0.0006080262],"study_design_scores_gemma":[0.000010110905,0.00012394137,0.0016270911,0.0000032123946,0.000013983487,0.00006824468,0.0000090771355,0.00058576535,0.9962857,0.00002075763,0.001249865,0.000002209759],"about_ca_topic_score_codex":0.00021228372,"about_ca_topic_score_gemma":0.00026751394,"teacher_disagreement_score":0.0015953599,"about_ca_system_score_codex":0.00028471224,"about_ca_system_score_gemma":0.00017834253,"threshold_uncertainty_score":0.005337},"labels":[],"label_agreement":null},{"id":"W2511378889","doi":"10.1186/s13045-016-0312-z","title":"Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Ladies Leukemia League; Stichting Kinderen Kankervrij; Children’s Oncology Group; Takeda Oncology; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; Hematology; Medicine; Chemotherapy; Internal medicine; Oncology; Proteasome inhibitor; Proteasome; Multiple myeloma; Biology; Genetics","score_opus":0.00805399605000955,"score_gpt":0.2607409526006481,"score_spread":0.25268695655063855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511378889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898034,0.0006522664,0.000056792316,0.000010527858,0.000001973054,0.0000068451545,0.000088188615,0.000004472799,0.00019853229],"genre_scores_gemma":[0.99944395,0.0001960449,0.00008160482,0.000013586854,0.000004076476,0.000006200691,0.00018916145,0.00000183175,0.00006355784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997677,0.000049043,0.00002948112,0.00005608797,0.000059619077,0.000038094324],"domain_scores_gemma":[0.99949706,0.00009330998,0.00026708693,0.000023796481,0.00004623035,0.000072508374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028050152,0.00015727062,0.00046204918,0.00047929882,0.0001506382,0.00038157738,0.00014284164,0.00020668165,0.00075473427],"category_scores_gemma":[0.0009209131,0.00011708825,0.0001765267,0.0005994921,0.00021235013,0.00015286305,0.00016716987,0.0003318622,0.00018385905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024891575,0.000082936036,0.94164395,0.00009235593,0.00009382867,0.000978713,0.00040139977,0.00023688098,0.04419706,0.00004121107,0.00016735018,0.009575066],"study_design_scores_gemma":[0.000027413269,0.0008063142,0.9906266,0.000007398615,0.00004258084,0.0032651073,0.00012880834,0.00018520138,0.0043047634,0.00001782511,0.00058372173,0.0000043234586],"about_ca_topic_score_codex":0.00051346805,"about_ca_topic_score_gemma":0.00055897894,"teacher_disagreement_score":0.00075473427,"about_ca_system_score_codex":0.00028170674,"about_ca_system_score_gemma":0.00011179074,"threshold_uncertainty_score":0.0025248528},"labels":[],"label_agreement":null},{"id":"W2551670998","doi":"10.1186/s13045-016-0349-z","title":"A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Institute of Cancer Research; China Scholarship Council; University of Alberta; University of Ottawa; Li Ka Shing Foundation","keywords":"Regulator; Wnt signaling pathway; Cancer research; Biology; SOX2; Cell culture; Molecular biology; Transcriptional regulation; Lymphoma; Cell growth; Gene expression; Transcription factor; Cell biology; Signal transduction; Gene; Immunology; Genetics","score_opus":0.01148644348260239,"score_gpt":0.26496089130228523,"score_spread":0.2534744478196828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551670998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978052,0.0003268106,0.0013682242,0.00001592964,0.0000033291326,0.0000084573285,0.00010327158,0.000039331415,0.00032946022],"genre_scores_gemma":[0.9984773,0.00011209875,0.0006988635,0.00001057625,0.0000045837833,0.00001079903,0.00017416441,0.0000062431122,0.0005052475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988544,0.000012717159,0.000007861159,0.000029110308,0.00004200857,0.000022954762],"domain_scores_gemma":[0.99986386,0.000014452507,0.00005784339,0.000009026965,0.000018082956,0.00003666574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009975523,0.00018162199,0.00017156974,0.00031379232,0.00012854762,0.0002827195,0.00011750647,0.00010842226,0.0007921801],"category_scores_gemma":[0.00010395796,0.000108861204,0.00012491502,0.00014039414,0.00017088403,0.0001281429,0.00014998406,0.00017544084,0.00022615238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063198764,0.000008819443,0.0025444122,0.000007598181,0.0000015451607,0.00009413104,0.000013010311,0.000018533892,0.9966163,0.000034738892,0.000014197235,0.00058346713],"study_design_scores_gemma":[0.00003076932,0.00043619538,0.18224107,0.000007440361,0.000026679745,0.0025172173,0.00019459275,0.00314277,0.8089361,0.00017330445,0.002285254,0.0000085726615],"about_ca_topic_score_codex":0.0002846669,"about_ca_topic_score_gemma":0.00067220646,"teacher_disagreement_score":0.0007921801,"about_ca_system_score_codex":0.00018660526,"about_ca_system_score_gemma":0.00013058363,"threshold_uncertainty_score":0.002650082},"labels":[],"label_agreement":null},{"id":"W2551906795","doi":"10.1186/s13045-016-0354-2","title":"High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide","year":2016,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Hematology; Oncology; Refractory (planetary science); Thalidomide; Immunohistochemistry; Biology","score_opus":0.013447504030600493,"score_gpt":0.25234843161951775,"score_spread":0.23890092758891726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551906795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948289,0.0010666136,0.00018427217,0.0019011499,0.00004613799,0.000015358526,0.00012519976,0.000017440905,0.001814955],"genre_scores_gemma":[0.997755,0.00045167148,0.00022648052,0.0005686421,0.00021284034,0.00001130938,0.00010812321,0.0000031141576,0.0006628041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998481,0.000031541702,0.000020721252,0.000028755197,0.00003070011,0.000040037667],"domain_scores_gemma":[0.999634,0.00011183203,0.00009700886,0.000029191273,0.000057850008,0.000070102265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000169739,0.00014357892,0.00031856002,0.00020677724,0.00041803007,0.00034601765,0.00015984669,0.00045607128,0.0010233262],"category_scores_gemma":[0.00080985157,0.000078675585,0.0001480382,0.00032460107,0.00020035781,0.00022262195,0.00012157388,0.0004736319,0.00028086975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015631769,0.00011381701,0.9343736,0.00006727049,0.000032277843,0.024013476,0.00019184499,0.00014458175,0.009015383,0.0001473389,0.0025057804,0.027831584],"study_design_scores_gemma":[0.00009718617,0.0007233157,0.8733608,0.000035252382,0.00009627898,0.112127304,0.0004043138,0.0017484729,0.0029641946,0.0005852709,0.00783662,0.00002095242],"about_ca_topic_score_codex":0.0005805262,"about_ca_topic_score_gemma":0.0010468857,"teacher_disagreement_score":0.0010233262,"about_ca_system_score_codex":0.0002639999,"about_ca_system_score_gemma":0.00021171694,"threshold_uncertainty_score":0.0034233332},"labels":[],"label_agreement":null},{"id":"W2586463853","doi":"10.1186/s13045-017-0413-3","title":"Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia","year":2017,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Toronto; St. Michael's Hospital","funders":"Ministry of Education of the People's Republic of China; Canadian Institutes of Health Research; European Hematology Association; China Scholarship Council; Canadian Blood Services; Anhui Medical University","keywords":"Platelet; Immune thrombocytopenia; Medicine; Immunology; Clearance; Hematology; Immune system; Biomarker; Asialoglycoprotein receptor; Internal medicine; In vitro; Biology","score_opus":0.030693644630915735,"score_gpt":0.32656672953132027,"score_spread":0.29587308490040454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586463853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9207488,0.025569724,0.002610323,0.021708561,0.00062970194,0.000112441594,0.0005593451,0.00016589904,0.027895167],"genre_scores_gemma":[0.98958546,0.0027191234,0.00089512917,0.0029213014,0.0007550553,0.000042790096,0.00029444633,0.0000144585865,0.002772116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945563,0.0001779438,0.00005539207,0.000058002744,0.00020069804,0.00005236919],"domain_scores_gemma":[0.9980075,0.0009892067,0.00039249694,0.0001241178,0.00037383055,0.00011293266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004618563,0.0001964966,0.0003597867,0.0003769046,0.00018129342,0.00040151126,0.00014444072,0.0007668476,0.001534899],"category_scores_gemma":[0.0035776566,0.000066451306,0.00013075072,0.00059118774,0.00020367577,0.00031971524,0.00014745539,0.0008853332,0.0006692771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049507194,0.00042395346,0.6367359,0.00029724068,0.00012103351,0.015584513,0.0003695859,0.0006002955,0.032892864,0.0011354632,0.019905541,0.2869829],"study_design_scores_gemma":[0.00014343258,0.0034623211,0.8715464,0.00014572564,0.00015543467,0.059115443,0.00031886494,0.0043437732,0.017260315,0.0025776953,0.0408857,0.000044850647],"about_ca_topic_score_codex":0.0001882973,"about_ca_topic_score_gemma":0.00027548286,"teacher_disagreement_score":0.001534899,"about_ca_system_score_codex":0.00033056183,"about_ca_system_score_gemma":0.00011364673,"threshold_uncertainty_score":0.0051347613},"labels":[],"label_agreement":null},{"id":"W2589237569","doi":"10.1186/s13045-017-0417-z","title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Medicine; Placebo; Myelofibrosis; Internal medicine; Randomized controlled trial; Population; Adverse effect; Clinical endpoint; Surgery; Pathology; Bone marrow","score_opus":0.03706328763014617,"score_gpt":0.3607162889532588,"score_spread":0.32365300132311264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589237569","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42532998,0.5260835,0.0041929907,0.015181026,0.0030693172,0.0039049294,0.0104355,0.00047853505,0.0113241],"genre_scores_gemma":[0.7774659,0.15889286,0.008297149,0.02502229,0.0036355138,0.0059571154,0.017414127,0.0001438973,0.00317121],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99655616,0.0019927053,0.0004356706,0.00019006159,0.00061537453,0.00021005403],"domain_scores_gemma":[0.99221003,0.0029209096,0.0026125833,0.00037696311,0.0011684111,0.0007111317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012672661,0.00060193916,0.0024221716,0.00045201046,0.00043423395,0.0017444255,0.0010043636,0.0018662909,0.0025588523],"category_scores_gemma":[0.0076928,0.0003012504,0.00254236,0.00077440555,0.0005524384,0.0011203464,0.00047555997,0.0023298808,0.0004441157],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5091101,0.0031531374,0.0154520925,0.01262985,0.010877486,0.00027226392,0.00041702585,0.00090882747,0.005662626,0.001272224,0.034789354,0.40545496],"study_design_scores_gemma":[0.7094121,0.06750567,0.08063069,0.0060342476,0.018899594,0.001021035,0.00027638747,0.0014144224,0.0027042367,0.0012386083,0.110669285,0.00019370666],"about_ca_topic_score_codex":0.0008832482,"about_ca_topic_score_gemma":0.0027063913,"teacher_disagreement_score":0.012672661,"about_ca_system_score_codex":0.0010035532,"about_ca_system_score_gemma":0.001562725,"threshold_uncertainty_score":0.06702024},"labels":[],"label_agreement":null},{"id":"W2616354644","doi":"10.1186/s13045-017-0465-4","title":"An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; University of Texas Health Science Center at San Antonio; Children’s Oncology Group; Cancer Research Society; Texas Children's Hospital; National Cancer Institute; National Institutes of Health; Children's Hospital of Philadelphia","keywords":"MEG3; microRNA; Osteosarcoma; Methylation; Computational biology; DNA methylation; Biology; Long non-coding RNA; Bioinformatics; Cancer research; Oncology; Medicine; Genetics; Gene expression; RNA; Gene","score_opus":0.02975235449571328,"score_gpt":0.3830397856403506,"score_spread":0.35328743114463734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616354644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937028,0.00018540712,0.0014826905,0.00004235554,0.0000044019635,0.00002675295,0.0043148687,0.00005111056,0.00018958899],"genre_scores_gemma":[0.9729844,0.00008010163,0.0025354978,0.00003698191,0.000007822267,0.00008746629,0.024098832,0.000025592592,0.00014349882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984633,0.00036848747,0.00022550208,0.0005873998,0.00022165818,0.00013372832],"domain_scores_gemma":[0.9969217,0.0013411745,0.0008241743,0.0004718571,0.00027596197,0.00016515554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025508385,0.0004078508,0.000639387,0.0012891183,0.0003091045,0.0006529024,0.00050985534,0.00047306382,0.0007032409],"category_scores_gemma":[0.004698854,0.00017252023,0.00067997864,0.001205813,0.00034080408,0.00025776742,0.0010557969,0.0003930383,0.00021479104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014639796,0.00011159314,0.96149516,0.00016347175,0.00082209497,0.00014762598,0.00017120095,0.0027914788,0.018310841,0.00011149825,0.0009046672,0.013506216],"study_design_scores_gemma":[0.0001165599,0.0002914338,0.97878665,0.000026202662,0.000518494,0.00062931096,0.00019158938,0.011148188,0.006085743,0.00053134584,0.0016487577,0.000025600319],"about_ca_topic_score_codex":0.002357948,"about_ca_topic_score_gemma":0.004724269,"teacher_disagreement_score":0.0025508385,"about_ca_system_score_codex":0.00035789338,"about_ca_system_score_gemma":0.0005486939,"threshold_uncertainty_score":0.013490319},"labels":[],"label_agreement":null},{"id":"W2625950020","doi":"10.1186/s13045-017-0490-3","title":"Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Cancer Society; Cancer Research Society","keywords":"Immunology; Bone marrow; Transplantation; T cell; CD8; Stem cell; Haematopoiesis; Biology; Granzyme; Granzyme B; Lymphopoiesis; Immune system; Medicine; Internal medicine; Cell biology; Perforin","score_opus":0.015609888528913176,"score_gpt":0.2622641932477187,"score_spread":0.24665430471880553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625950020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587077,0.0017123042,0.0008617572,0.000042109063,0.000041862088,0.000038923794,0.00009849876,0.000056485886,0.0012771899],"genre_scores_gemma":[0.9973483,0.00085044437,0.00087160734,0.00003074937,0.00004261187,0.000024995437,0.0002003318,0.000009686678,0.0006213638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989796,0.000026376212,0.000012309883,0.000010518081,0.000026045984,0.000026706808],"domain_scores_gemma":[0.9998503,0.000035977064,0.00003671409,0.000014594777,0.0000134794645,0.000048895636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015884812,0.00023252229,0.00015350764,0.00024303395,0.000084659376,0.00023034347,0.00011938209,0.00014460266,0.0009913964],"category_scores_gemma":[0.00017810853,0.000039119946,0.00015388471,0.000106221334,0.00017530475,0.00012007806,0.00018393763,0.0005355135,0.00020408597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013119592,0.00052952435,0.0012498337,0.00011998254,0.000011746392,0.00020179962,0.000041393032,0.00017623599,0.98127544,0.00014012647,0.00018459582,0.014757354],"study_design_scores_gemma":[0.00013052812,0.0044943457,0.011064628,0.00002872224,0.00006131392,0.0006430793,0.00004041726,0.0007578016,0.9779016,0.00011744154,0.0047550197,0.0000051343677],"about_ca_topic_score_codex":0.000046274152,"about_ca_topic_score_gemma":0.00012558611,"teacher_disagreement_score":0.0009913964,"about_ca_system_score_codex":0.00007072136,"about_ca_system_score_gemma":0.00013538027,"threshold_uncertainty_score":0.0033165812},"labels":[],"label_agreement":null},{"id":"W2626414898","doi":"10.1186/s13045-017-0492-1","title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","year":2017,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"microRNA; Multiple myeloma; Epigenetics; Hematology; Drug resistance; Medicine; Internal medicine; Oncology; Drug; Cancer research; Bioinformatics; Pharmacology; Computational biology; Biology; Genetics; Gene","score_opus":0.0652217907511443,"score_gpt":0.4123141270484581,"score_spread":0.3470923362973138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626414898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018475988,0.9983536,0.00012128259,0.00030603938,0.00015252875,0.0000036057188,0.000015387106,0.000007647996,0.00085519935],"genre_scores_gemma":[0.0009900139,0.9980045,0.00019316915,0.0001744983,0.00013241409,0.0000057546695,0.000023339442,0.0000013556053,0.0004750309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998901,0.000019412275,0.000019711206,0.000019077355,0.000039878534,0.000011800647],"domain_scores_gemma":[0.99984753,0.000065178436,0.000023619597,0.0000035864107,0.00004367072,0.00001645092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000350772,0.0005136411,0.00083457795,0.0013434463,0.00025260978,0.0007232808,0.0004606263,0.00075700716,0.0022914165],"category_scores_gemma":[0.0004388006,0.00017471767,0.0003459982,0.0011304725,0.00027260804,0.0008233786,0.00054874463,0.0011872839,0.0010602974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006467261,0.00006391587,0.0003648738,0.0126991635,0.00009494961,0.00034071642,0.00008133423,0.0003154967,0.0029472746,0.0035324537,0.022203067,0.95729196],"study_design_scores_gemma":[0.00001580476,0.00010429978,0.0014563556,0.0026046294,0.0001447863,0.0024963245,0.000077085744,0.00015019512,0.0011908076,0.0022379714,0.98950154,0.000020200452],"about_ca_topic_score_codex":0.00062283006,"about_ca_topic_score_gemma":0.0013782122,"teacher_disagreement_score":0.0022914165,"about_ca_system_score_codex":0.0004605982,"about_ca_system_score_gemma":0.0009586959,"threshold_uncertainty_score":0.007665515},"labels":[],"label_agreement":null},{"id":"W2734041100","doi":"10.1186/s13045-017-0499-7","title":"The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"Priority Academic Program Development of Jiangsu Higher Education Institutions; Government of Jiangsu Province; Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Apoptosis; Molecular biology; Biology; Flow cytometry; Ubiquitin; Immunoprecipitation; Cell growth; Multiple myeloma; Downregulation and upregulation; Cancer research; Chromatin immunoprecipitation; Cell culture; Chemistry; Gene expression; Immunology; Biochemistry; Promoter; Gene","score_opus":0.022622217207112476,"score_gpt":0.2876465876844599,"score_spread":0.2650243704773474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734041100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072874,0.0040505696,0.0034968192,0.00013185617,0.000057861416,0.000033228316,0.00039148497,0.00013206332,0.0009773124],"genre_scores_gemma":[0.99481225,0.0013077811,0.0013146976,0.000059093865,0.000013006603,0.00003191434,0.0005452886,0.0000128460515,0.0019031143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998553,0.000015371486,0.0000132894465,0.000035730132,0.000034170265,0.00004618847],"domain_scores_gemma":[0.9999373,0.0000068950662,0.00001890608,0.0000103807515,0.000010079512,0.00001630165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014426303,0.00040142552,0.00032297644,0.00022849403,0.00017899672,0.00027230594,0.00018719798,0.00031896663,0.00071681105],"category_scores_gemma":[0.00009670574,0.00009517202,0.00027907814,0.00027705322,0.0002108334,0.00015161464,0.0001642329,0.00037883487,0.00019586753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017772058,0.000045629713,0.000447723,0.00005146134,0.000013172688,0.00004698912,0.000007424095,0.00004294551,0.9976509,0.00005371564,0.000067366665,0.0013950154],"study_design_scores_gemma":[0.00001851324,0.00013671137,0.0036033131,0.000003317902,0.000021879263,0.0001280199,0.000011078728,0.0005901126,0.9935348,0.00002285064,0.001926843,0.0000025831125],"about_ca_topic_score_codex":0.00035678403,"about_ca_topic_score_gemma":0.00051175203,"teacher_disagreement_score":0.00071681105,"about_ca_system_score_codex":0.0003298309,"about_ca_system_score_gemma":0.00016060278,"threshold_uncertainty_score":0.0023979545},"labels":[],"label_agreement":null},{"id":"W2759277150","doi":"10.1186/s13045-017-0527-7","title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharma; Genentech; AOP Orphan; CTI Biopharma; Incyte; Baxalta; Ariad Pharmaceuticals; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Hazard ratio; Randomized controlled trial; International Prognostic Scoring System; Clinical endpoint; Anemia; Hematology; Placebo; Survival analysis; Proportional hazards model; Clinical trial; Subgroup analysis; Surgery; Confidence interval; Bone marrow; Myelodysplastic syndromes; Pathology","score_opus":0.0497649413758295,"score_gpt":0.3819046456399105,"score_spread":0.332139704264081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759277150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9101316,0.073651604,0.002989886,0.00018774146,0.0002487161,0.00073502527,0.010019092,0.00009698042,0.0019393337],"genre_scores_gemma":[0.9874106,0.0042732903,0.0009788951,0.00019112974,0.00022800597,0.00064832426,0.0057534887,0.000022485769,0.00049374317],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99328846,0.0039269766,0.00086007244,0.0010248128,0.0006492737,0.00025039705],"domain_scores_gemma":[0.9940263,0.0030516204,0.0016663809,0.00058554637,0.0004230124,0.00024707956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01027473,0.0014610174,0.005188711,0.0012450318,0.00018633377,0.0011330697,0.00073942007,0.0008007174,0.0018611922],"category_scores_gemma":[0.007005092,0.0005512846,0.014052318,0.001390881,0.0002726083,0.00066188193,0.00093687215,0.0007733499,0.00016433143],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24595234,0.00025306296,0.16599509,0.006755828,0.54850143,0.0002242024,0.00015757994,0.0037068762,0.0025523326,0.0001820272,0.0022661593,0.023453051],"study_design_scores_gemma":[0.02489807,0.019109271,0.5107527,0.00076150877,0.43221164,0.00045109942,0.00027239733,0.005020105,0.0013199493,0.0003717096,0.0046558864,0.00017572874],"about_ca_topic_score_codex":0.0012561388,"about_ca_topic_score_gemma":0.0026826374,"teacher_disagreement_score":0.01027473,"about_ca_system_score_codex":0.00053168775,"about_ca_system_score_gemma":0.0005433262,"threshold_uncertainty_score":0.054338574},"labels":[],"label_agreement":null},{"id":"W2766193356","doi":"10.1186/s13045-017-0538-4","title":"Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis","year":2017,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"microRNA; Oncomir; Multiple myeloma; Pathogenesis; Cancer research; Suppressor; Biology; Drug resistance; Hematology; Function (biology); Mechanism (biology); Bioinformatics; Gene; Medicine; Immunology; Genetics","score_opus":0.02445086020801732,"score_gpt":0.3420576218357852,"score_spread":0.31760676162776785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766193356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018105446,0.9982925,0.00016531578,0.00032226834,0.00019316647,0.0000024734516,0.000010165397,0.00000766237,0.0008253694],"genre_scores_gemma":[0.0011693031,0.9977246,0.00021051682,0.00014658886,0.00019580004,0.000005024714,0.000017423796,0.0000016206066,0.0005291726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998777,0.000019478517,0.000017756714,0.000025330191,0.00004418312,0.000015453143],"domain_scores_gemma":[0.9997665,0.000098010656,0.00003515506,0.000006870739,0.00006125664,0.000032204058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004316443,0.00060593477,0.000842948,0.0014328014,0.00028260227,0.0009410667,0.00059240445,0.0010912826,0.0020870245],"category_scores_gemma":[0.0005125695,0.00019893904,0.00026697502,0.0014984437,0.0005209367,0.0010998694,0.00077974907,0.0013804357,0.0013151184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000795742,0.000059209462,0.00037897576,0.008204165,0.000056404817,0.00039904597,0.00007838027,0.0004597726,0.003871893,0.006014208,0.018110162,0.9622881],"study_design_scores_gemma":[0.000009918109,0.00008925992,0.0012678108,0.001933731,0.00008306462,0.002257417,0.00008218971,0.00017484762,0.0015015806,0.003872415,0.98870647,0.000021283906],"about_ca_topic_score_codex":0.00059653714,"about_ca_topic_score_gemma":0.0009603227,"teacher_disagreement_score":0.0020870245,"about_ca_system_score_codex":0.0005979654,"about_ca_system_score_gemma":0.0011362095,"threshold_uncertainty_score":0.00698179},"labels":[],"label_agreement":null},{"id":"W2795765610","doi":"10.1186/s13045-018-0589-1","title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway","year":2018,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Clinical trial; Hematology; PD-L1; Oncology; Immune system; Immunotherapy; Bioinformatics; Cancer research; Pharmacology; Internal medicine; Immunology; Biology","score_opus":0.12021023957209341,"score_gpt":0.43454534948459955,"score_spread":0.3143351099125061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795765610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001959311,0.9982868,0.00018545343,0.00030438922,0.00017383666,0.000005428607,0.000012969419,0.000007703849,0.00082741654],"genre_scores_gemma":[0.001218598,0.99751943,0.00025772193,0.0002287132,0.00015275199,0.000008652124,0.00002816956,0.0000015205056,0.000584343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988115,0.000021776297,0.00001657728,0.000021341502,0.000045643574,0.000013547773],"domain_scores_gemma":[0.99985504,0.000061761384,0.000021286229,0.000005276898,0.000042108608,0.000014518579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003850754,0.00056686817,0.00096940977,0.0017477045,0.00023068306,0.0007903456,0.0005886744,0.00091838656,0.0024731406],"category_scores_gemma":[0.00038901877,0.00018043666,0.00053469086,0.0011530673,0.00032986517,0.0010558617,0.0005093237,0.0016998614,0.0012078104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009204063,0.00012613513,0.00025942852,0.017257752,0.00010630742,0.00034285558,0.00008076305,0.00038514246,0.00510611,0.004076789,0.021544784,0.9506219],"study_design_scores_gemma":[0.00002576372,0.00016762095,0.00077397266,0.0024454838,0.0001311867,0.0022689954,0.000050133585,0.00012458907,0.0013899227,0.0017307752,0.9908737,0.000017927852],"about_ca_topic_score_codex":0.00059220963,"about_ca_topic_score_gemma":0.0010444989,"teacher_disagreement_score":0.0024731406,"about_ca_system_score_codex":0.0004610911,"about_ca_system_score_gemma":0.00073274353,"threshold_uncertainty_score":0.008273482},"labels":[],"label_agreement":null},{"id":"W2807425977","doi":"10.1186/s13045-018-0618-0","title":"miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Natural Science Foundation of Guangdong Province; National Natural Science Foundation of China","keywords":"Glioblastoma; Autophagy; Cancer research; Hematology; Signal transduction; Temozolomide; Medicine; Pathway analysis; STAT3; Oncology; Chemistry; Internal medicine; Apoptosis; Gene; Gene expression; Biochemistry","score_opus":0.00963251872505067,"score_gpt":0.30180095130822965,"score_spread":0.292168432583179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807425977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932087,0.0030693284,0.001291585,0.00017653487,0.00006469036,0.000032986954,0.0003782761,0.00015861212,0.0016191818],"genre_scores_gemma":[0.9966273,0.0011447977,0.00085980975,0.00007842746,0.000011316891,0.000025587982,0.00043189278,0.000012364127,0.00080862484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998863,0.000012779831,0.00001708334,0.000016907645,0.00003443231,0.00003254155],"domain_scores_gemma":[0.99995387,0.0000055716105,0.000015885564,0.000005272097,0.000007663054,0.000011844844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001249037,0.00030207928,0.00032520323,0.00031910164,0.00022749972,0.0002918747,0.00012826099,0.00020067593,0.0011271369],"category_scores_gemma":[0.00009507632,0.00011024894,0.00035536068,0.00022093832,0.0002367077,0.00015230247,0.00015756558,0.00044277104,0.00036665177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046321284,0.00011733018,0.0009985752,0.00010143221,0.000018050932,0.00009864901,0.000024226076,0.00013462853,0.99369663,0.000119034055,0.00026937918,0.0039589326],"study_design_scores_gemma":[0.000069708905,0.00085879315,0.011515866,0.000013678148,0.00007525127,0.00041591597,0.00004937872,0.0017172594,0.981167,0.000079619254,0.0040287133,0.000008872802],"about_ca_topic_score_codex":0.00065851357,"about_ca_topic_score_gemma":0.0011774718,"teacher_disagreement_score":0.0011271369,"about_ca_system_score_codex":0.0003791732,"about_ca_system_score_gemma":0.00026597656,"threshold_uncertainty_score":0.0037705898},"labels":[],"label_agreement":null},{"id":"W2808120958","doi":"10.1186/s13045-018-0625-1","title":"Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Microvesicles; Exosome; Tumor microenvironment; Cancer research; Angiogenesis; Nonalcoholic fatty liver disease; Cell culture; Biology; Cell biology; Internal medicine; Chemistry; Medicine; microRNA; Fatty liver; Biochemistry; Disease","score_opus":0.009077484053554135,"score_gpt":0.2384835026020161,"score_spread":0.22940601854846196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808120958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721296,0.0024769509,0.0075019826,0.000144375,0.0000712408,0.000046657184,0.0006416899,0.00009298368,0.0018111273],"genre_scores_gemma":[0.9933797,0.0014360872,0.0024849295,0.000056219746,0.000022609836,0.000037882914,0.0006221173,0.000022741056,0.0019377186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999132,0.000014059895,0.000010395423,0.000017403412,0.000023957482,0.000020928475],"domain_scores_gemma":[0.999913,0.000016582315,0.00002016014,0.000014295638,0.000019902098,0.000016038919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013638534,0.0002567001,0.00017340438,0.00017054853,0.00015902393,0.00028714247,0.000060054346,0.00016922559,0.0011435547],"category_scores_gemma":[0.00009633262,0.00007632472,0.0003307904,0.00016683896,0.00014259547,0.00022798483,0.00028215133,0.0003740423,0.00037889174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023631018,0.000028541972,0.0015755184,0.0000728669,0.000011255669,0.00027517125,0.000046518482,0.0000731576,0.99486285,0.00018025943,0.00008381324,0.002553657],"study_design_scores_gemma":[0.00004401258,0.00041231944,0.01598923,0.000017180664,0.000052702795,0.0013372253,0.00020065717,0.0008352782,0.97242516,0.00022889297,0.008445236,0.000012079072],"about_ca_topic_score_codex":0.00015841144,"about_ca_topic_score_gemma":0.00026177394,"teacher_disagreement_score":0.0011435547,"about_ca_system_score_codex":0.00012373237,"about_ca_system_score_gemma":0.00012784437,"threshold_uncertainty_score":0.0038255453},"labels":[],"label_agreement":null},{"id":"W2891596347","doi":"10.1186/s13045-018-0661-x","title":"A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","year":2018,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Fondazione Regionale per la Ricerca Biomedica; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Vismodegib; Myelofibrosis; Medicine; Internal medicine; Hematology; Oncology; Phases of clinical research; Clinical trial; Bone marrow","score_opus":0.022472772919080175,"score_gpt":0.33131442023480595,"score_spread":0.3088416473157258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891596347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920564,0.0012295367,0.00067725335,0.0003151768,0.00006658496,0.0029154052,0.0008421572,0.00007530701,0.0018221189],"genre_scores_gemma":[0.9907831,0.0006199425,0.0017407107,0.0006518878,0.00010658123,0.0030119582,0.0018232039,0.000018528795,0.0012441841],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955815,0.00018834868,0.000029768053,0.000085225634,0.000041732157,0.00009680392],"domain_scores_gemma":[0.99912316,0.00011124114,0.00014621356,0.00007467523,0.000048758975,0.00049596844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015864725,0.0010799381,0.0016807169,0.00033076075,0.00043462883,0.0007661329,0.0007405183,0.0009795005,0.0048688175],"category_scores_gemma":[0.0008563673,0.0004759913,0.001086145,0.0002985001,0.0007463721,0.0007541318,0.0003403737,0.002633234,0.0011666056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7187463,0.10325571,0.013953031,0.00070282695,0.0011836031,0.0004533393,0.00027431385,0.0019030817,0.066348486,0.00028426,0.0042895894,0.088605545],"study_design_scores_gemma":[0.41709843,0.56035274,0.013793343,0.000041008007,0.00043029108,0.0004389366,0.000041884825,0.0009547977,0.0042038737,0.00015140433,0.00247059,0.000022639946],"about_ca_topic_score_codex":0.00064460584,"about_ca_topic_score_gemma":0.0012666658,"teacher_disagreement_score":0.0048688175,"about_ca_system_score_codex":0.00082353473,"about_ca_system_score_gemma":0.0016934815,"threshold_uncertainty_score":0.016287804},"labels":[],"label_agreement":null},{"id":"W2947538095","doi":"10.1186/s13045-019-0731-8","title":"Emerging therapies for non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Natural Science Foundation of China","keywords":"Medicine; Hematology; Internal medicine; Lung cancer; Oncology; Intensive care medicine; Cancer; Medical physics","score_opus":0.04225786029802803,"score_gpt":0.44959770447566233,"score_spread":0.4073398441776343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947538095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010041946,0.9979863,0.00014785134,0.000284599,0.00027561194,0.0000059424456,0.00001672984,0.000008082596,0.0011744805],"genre_scores_gemma":[0.00064033177,0.99781007,0.00022383379,0.0002831711,0.00022756279,0.000006800719,0.000035296893,0.0000015123774,0.0007715269],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998691,0.000022402068,0.0000172712,0.000023040384,0.00005325387,0.000014891618],"domain_scores_gemma":[0.99981326,0.00008166917,0.000025880836,0.000006828085,0.000052584946,0.000019892692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003827886,0.00066927646,0.00087507407,0.0018578104,0.0002464576,0.0006876735,0.0005889887,0.00077572913,0.0042110947],"category_scores_gemma":[0.0004020017,0.00017294665,0.0004916626,0.0012212924,0.00029215642,0.0010561736,0.00054139073,0.0020945529,0.0020808824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048232607,0.00006575787,0.00011513922,0.009195891,0.000060953706,0.00017197251,0.000033246633,0.00025857872,0.0018425868,0.003220181,0.028710278,0.9562772],"study_design_scores_gemma":[0.000014308546,0.00008418724,0.00044536617,0.001971395,0.000072794915,0.0011603095,0.000030006664,0.0000831919,0.00038189453,0.0015776868,0.99416924,0.000009648907],"about_ca_topic_score_codex":0.0005450719,"about_ca_topic_score_gemma":0.0014949704,"teacher_disagreement_score":0.0042110947,"about_ca_system_score_codex":0.0004356634,"about_ca_system_score_gemma":0.00065765466,"threshold_uncertainty_score":0.014087498},"labels":[],"label_agreement":null},{"id":"W2960151143","doi":"10.1186/s13045-019-0766-x","title":"K+-Cl− cotransporter 1 (KCC1): a housekeeping membrane protein that plays key supplemental roles in hematopoietic and cancer cells","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"Canadian Institutes of Health Research; Kidney Foundation of Canada","keywords":"Housekeeping gene; Gene isoform; Cotransporter; Ouabain; Biology; Chemistry; Gene; Biochemistry; Gene expression","score_opus":0.05100090609693871,"score_gpt":0.3489391860766924,"score_spread":0.2979382799797537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960151143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019188764,0.9981583,0.0001403923,0.0002832656,0.00025772888,0.0000027706733,0.000027056767,0.000011646875,0.00092705275],"genre_scores_gemma":[0.00075500726,0.99814117,0.000127231,0.00014805348,0.00014235056,0.0000031191234,0.000057234185,0.0000014321222,0.00062450574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998841,0.000011835007,0.000021428652,0.000028909832,0.000041379484,0.000012243399],"domain_scores_gemma":[0.9998043,0.000059654307,0.000035582205,0.0000055469527,0.00006880137,0.000026047543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028888063,0.0007743978,0.0010390165,0.0017380939,0.00026203212,0.00068093126,0.00064037164,0.0006652187,0.002405243],"category_scores_gemma":[0.0004260411,0.00018409887,0.00029171916,0.0019565374,0.00044905063,0.0010323166,0.0005084337,0.0013559775,0.0020297214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009051125,0.00005236067,0.00037425387,0.013991924,0.00007310563,0.00026490583,0.000054456184,0.00028019844,0.003996045,0.0026767822,0.035719868,0.94242567],"study_design_scores_gemma":[0.000008618738,0.000057559086,0.00088810077,0.0010977993,0.000073753974,0.0015235867,0.000036472964,0.000051163064,0.0007096386,0.0008372869,0.9947018,0.000014154673],"about_ca_topic_score_codex":0.0010405381,"about_ca_topic_score_gemma":0.0013714116,"teacher_disagreement_score":0.002405243,"about_ca_system_score_codex":0.00056351017,"about_ca_system_score_gemma":0.00097014057,"threshold_uncertainty_score":0.008046389},"labels":[],"label_agreement":null},{"id":"W3005597885","doi":"10.1186/s13045-019-0842-2","title":"Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Nanjing Medical University; Government of Jiangsu Province; Jiangsu Science and Technology Department; National Natural Science Foundation of China","keywords":"Downregulation and upregulation; Cancer research; Metastasis; Biology; Carcinogenesis; microRNA; Lung cancer; Cancer; Long non-coding RNA; Small interfering RNA; Transfection; Cell migration; Cancer cell; Cell; Cell culture; Medicine; Pathology; Gene","score_opus":0.012067651255738717,"score_gpt":0.2867252466663514,"score_spread":0.2746575954106127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005597885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884071,0.0031471313,0.003703618,0.00022365089,0.00006601814,0.000046528752,0.0010791041,0.00039980345,0.0029271205],"genre_scores_gemma":[0.99575764,0.00058448286,0.0011128316,0.00006390308,0.000010082144,0.000040536917,0.00097014866,0.000024038525,0.0014363207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984396,0.000020156634,0.000014771202,0.000031988697,0.000043447573,0.000045603374],"domain_scores_gemma":[0.99991536,0.000012915273,0.000026749434,0.000006990202,0.000009490939,0.000028493041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011604199,0.00031805868,0.0002483764,0.0002653613,0.0003329977,0.0002832035,0.00023590763,0.0002169003,0.0029449821],"category_scores_gemma":[0.00015562313,0.00009471092,0.00044042905,0.0002774648,0.000312951,0.0001660771,0.00021746915,0.00043988446,0.0005668028],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039609682,0.00005068806,0.0013418671,0.00011326437,0.000014173156,0.00014925879,0.000026567828,0.00013864106,0.994117,0.00024076506,0.0004441575,0.002967466],"study_design_scores_gemma":[0.00012173919,0.00053765817,0.028919261,0.00001859851,0.00008016757,0.0007148738,0.00009484919,0.0038714046,0.9563215,0.00019812073,0.009102636,0.000019289564],"about_ca_topic_score_codex":0.0012336582,"about_ca_topic_score_gemma":0.0022595322,"teacher_disagreement_score":0.0029449821,"about_ca_system_score_codex":0.000470544,"about_ca_system_score_gemma":0.00035823695,"threshold_uncertainty_score":0.0098519325},"labels":[],"label_agreement":null},{"id":"W3033283870","doi":"10.1186/s13045-020-00894-2","title":"PTENP1 is a ceRNA for PTEN: it’s CRISPR clear","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health; National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Competing endogenous RNA; PTEN; CRISPR; Pseudogene; Biology; Computational biology; microRNA; Gene; Genetics; RNA; Bioinformatics; PI3K/AKT/mTOR pathway; Cancer research; Long non-coding RNA; Genome; Signal transduction","score_opus":0.03690685938457701,"score_gpt":0.3582913759758619,"score_spread":0.3213845165912849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033283870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6531637,0.0037291353,0.28729063,0.0043599545,0.0020265502,0.00031703996,0.002678048,0.0078097284,0.038625244],"genre_scores_gemma":[0.9219138,0.0013002702,0.052961927,0.0011105792,0.000064689404,0.0001560293,0.0017587413,0.0009285743,0.01980533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930525,0.00005161859,0.000039704068,0.00017624313,0.00033148078,0.00009570055],"domain_scores_gemma":[0.9995914,0.000114442926,0.00007911702,0.000088962646,0.000041892494,0.0000841022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042816886,0.00047917254,0.00044831325,0.00032369036,0.00053101947,0.0008902874,0.0005652374,0.0010081562,0.0040944344],"category_scores_gemma":[0.0007284016,0.0003256742,0.0004460181,0.00019850742,0.00076718495,0.0005471441,0.0008141168,0.0021742086,0.0018576593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008477002,0.00002649619,0.00039513034,0.00008439075,0.000015259962,0.00030537075,0.00005325992,0.0003412974,0.9865151,0.0023951072,0.0008399295,0.008943881],"study_design_scores_gemma":[0.000017288117,0.00014118437,0.0012327473,0.000013397524,0.000023127088,0.0010813575,0.000046316214,0.001551544,0.9660563,0.00056849245,0.029244948,0.000023224604],"about_ca_topic_score_codex":0.00089191797,"about_ca_topic_score_gemma":0.0015345906,"teacher_disagreement_score":0.0040944344,"about_ca_system_score_codex":0.00045760005,"about_ca_system_score_gemma":0.00065811013,"threshold_uncertainty_score":0.013697207},"labels":[],"label_agreement":null},{"id":"W3033907870","doi":"10.1186/s13045-020-00900-7","title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Genentech; H. Lundbeck A/S; Juno Therapeutics; Incyte; F. Hoffmann-La Roche; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; Servier; TG Therapeutics; Amgen","keywords":"Obinutuzumab; Rituximab; Medicine; Internal medicine; Hematology; Diffuse large B-cell lymphoma; Oncology; CHOP; Lymphoma; Vincristine; Chemotherapy; Cyclophosphamide","score_opus":0.03923046234378376,"score_gpt":0.34559044681061596,"score_spread":0.3063599844668322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033907870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884439,0.0023577197,0.0006788015,0.00045601008,0.0002988419,0.0057526864,0.0007736141,0.000057940604,0.001180565],"genre_scores_gemma":[0.9883831,0.001457113,0.0013263678,0.0008718935,0.00028420304,0.0050233155,0.0010023066,0.000020638357,0.0016310014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982889,0.0010888247,0.00007352809,0.00021904818,0.00010940284,0.00022022704],"domain_scores_gemma":[0.99823713,0.0004675188,0.00037084473,0.00015759488,0.00013135198,0.00063552853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037865958,0.0017158213,0.0034648015,0.0005232777,0.00052097446,0.0014680093,0.0011607568,0.0015835939,0.004447417],"category_scores_gemma":[0.0025298765,0.0008560814,0.0024327093,0.0005415303,0.0018653611,0.0011941617,0.0006936881,0.0030355367,0.0007085246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.983497,0.006332619,0.001021456,0.00020954569,0.0009247185,0.000024780544,0.00005173124,0.00023537532,0.0014665622,0.000055023833,0.00024768795,0.005933582],"study_design_scores_gemma":[0.9446724,0.052473083,0.0017210094,0.000014165144,0.0003369515,0.000017907683,0.000017810315,0.00019208982,0.00013041537,0.000068962,0.0003467898,0.000008387274],"about_ca_topic_score_codex":0.00096850033,"about_ca_topic_score_gemma":0.0033561157,"teacher_disagreement_score":0.004447417,"about_ca_system_score_codex":0.0011034328,"about_ca_system_score_gemma":0.0021621748,"threshold_uncertainty_score":0.02002567},"labels":[],"label_agreement":null},{"id":"W3037371046","doi":"10.1186/s13045-020-00922-1","title":"Oncolytic viruses for cancer immunotherapy","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":354,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Novo Nordisk Fonden; Biomedicum Helsinki-säätiö; Finska Läkaresällskapet; Helsingin Yliopisto","keywords":"Oncolytic virus; Immunotherapy; Virotherapy; Medicine; Clinical trial; Cancer; Cancer immunotherapy; Cancer research; Virology; Immunology; Virus; Oncology; Immune system; Internal medicine","score_opus":0.07781025988125306,"score_gpt":0.45459760217374107,"score_spread":0.376787342292488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037371046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013150013,0.99520016,0.0006926508,0.0003059637,0.0008668856,0.000015995707,0.000024759873,0.000023411389,0.0027386148],"genre_scores_gemma":[0.00097323704,0.9949738,0.0007981734,0.0004565017,0.00039437533,0.000031169133,0.00006953431,0.0000073571196,0.002295809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997451,0.000043381922,0.00002618817,0.000044624965,0.000113827635,0.000026844793],"domain_scores_gemma":[0.9998273,0.00007427888,0.000024670615,0.000009165759,0.000044655455,0.000019914592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059108465,0.0012333285,0.0008667442,0.0019030754,0.00035159627,0.0012232572,0.00073031813,0.001399683,0.004115644],"category_scores_gemma":[0.00052912807,0.00034987793,0.0005302115,0.0015368449,0.0006066921,0.0017760618,0.0009076093,0.0031216668,0.004283019],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005393691,0.00008146662,0.000120419376,0.010286646,0.000051459498,0.00023220057,0.0000984722,0.00065410876,0.008880973,0.013569098,0.052160047,0.91381115],"study_design_scores_gemma":[0.0000065993863,0.00003121797,0.000082367544,0.0006660703,0.000015769898,0.0004322409,0.000013543568,0.000041815667,0.00066701963,0.0016288001,0.9964071,0.0000075348676],"about_ca_topic_score_codex":0.0004620813,"about_ca_topic_score_gemma":0.0006200044,"teacher_disagreement_score":0.004115644,"about_ca_system_score_codex":0.0008359995,"about_ca_system_score_gemma":0.0008794223,"threshold_uncertainty_score":0.013768196},"labels":[],"label_agreement":null},{"id":"W3042325035","doi":"10.1186/s13045-020-00929-8","title":"Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"Daiichi Sankyo Europe; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; European Hematology Association; Celgene; Gilead Sciences; Servier; Ariad Pharmaceuticals; Amgen; Pfizer; Astellas Pharma","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Myeloid leukemia; Clinical trial; Oncology; Confidence interval","score_opus":0.0201375483975543,"score_gpt":0.31320000091298517,"score_spread":0.29306245251543084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042325035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959065,0.0023909481,0.00019617919,0.00027479374,0.000030474162,0.00006945608,0.0002767343,0.00001061263,0.0008443273],"genre_scores_gemma":[0.9985166,0.00030244453,0.00013215582,0.00022568817,0.000038994916,0.00006231304,0.0005610796,0.0000016817785,0.000158941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999498,0.00021444999,0.000041318246,0.000079958525,0.00007402018,0.00009222086],"domain_scores_gemma":[0.9991685,0.0002311937,0.00029679263,0.000039096398,0.00004011361,0.00022424373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014178791,0.00029128868,0.0007287185,0.00032896636,0.00022440695,0.0005305111,0.00025745574,0.0004680692,0.0015363336],"category_scores_gemma":[0.0014573296,0.0001037583,0.00093647774,0.00034422238,0.000290957,0.00039285774,0.00031313155,0.0008127584,0.00018022569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3536893,0.003215843,0.46533793,0.0005200681,0.0023932306,0.0002931407,0.00019152682,0.004717373,0.012123746,0.00047392902,0.0020188936,0.155025],"study_design_scores_gemma":[0.038579572,0.08566778,0.857555,0.00017105497,0.0025728042,0.00064450153,0.00015792098,0.005629238,0.003093342,0.001731281,0.004138493,0.0000589756],"about_ca_topic_score_codex":0.00032382278,"about_ca_topic_score_gemma":0.00075999426,"teacher_disagreement_score":0.0015363336,"about_ca_system_score_codex":0.0005800378,"about_ca_system_score_gemma":0.00048529945,"threshold_uncertainty_score":0.0074985027},"labels":[],"label_agreement":null},{"id":"W3042954004","doi":"10.1186/s13045-020-00930-1","title":"Role of CD47 in Hematological Malignancies","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Cancer Research Society","keywords":"CD47; Phagocytosis; Hematology; Cancer research; Medicine; Immune system; Immunology; Tumor microenvironment; Cancer; Metastasis; Internal medicine","score_opus":0.0367411651691547,"score_gpt":0.3331643473625536,"score_spread":0.2964231821933989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042954004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001840052,0.9988061,0.00005125032,0.00017206774,0.00012171492,0.00000238692,0.000008321711,0.0000040108184,0.0006500929],"genre_scores_gemma":[0.001194975,0.9978452,0.00008010855,0.00017762657,0.00015832235,0.000004522498,0.000025431811,8.168784e-7,0.0005130072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989974,0.000017113607,0.000014495983,0.000016703672,0.000038616232,0.00001321407],"domain_scores_gemma":[0.9999057,0.000040747072,0.000014437998,0.0000024659996,0.00002437657,0.000012197302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028192464,0.00049041706,0.00089769124,0.0013499337,0.00019948189,0.00070977287,0.0004259721,0.00071743876,0.0021598644],"category_scores_gemma":[0.00033094434,0.00016955087,0.0003674417,0.0009453866,0.0002667295,0.0006692608,0.00042845384,0.0012898983,0.0010880076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010897512,0.00006355158,0.0003218582,0.01126898,0.00007880685,0.00028956291,0.000055319517,0.00023110968,0.0031006264,0.0025949173,0.02889129,0.952995],"study_design_scores_gemma":[0.000025639458,0.00014408126,0.0013275478,0.0023905854,0.00012953774,0.0025239007,0.00004448509,0.00008502253,0.00095097127,0.001322137,0.99104226,0.0000137599445],"about_ca_topic_score_codex":0.0005663348,"about_ca_topic_score_gemma":0.00093711773,"teacher_disagreement_score":0.0021598644,"about_ca_system_score_codex":0.00036830988,"about_ca_system_score_gemma":0.0005991291,"threshold_uncertainty_score":0.007225454},"labels":[],"label_agreement":null},{"id":"W3092142993","doi":"10.1186/s13045-020-00971-6","title":"High-throughput approaches for precision medicine in high-grade serous ovarian cancer","year":2020,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Precision medicine; Serous carcinoma; Subtyping; Throughput; Personalized medicine; Medicine; Disease; Cancer; Ovarian cancer; Computer science; Oncology; Bioinformatics; Internal medicine; Biology; Pathology","score_opus":0.12953552146891298,"score_gpt":0.41269145702113835,"score_spread":0.2831559355522254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092142993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009417539,0.99841034,0.0003703937,0.00031605977,0.00017236113,0.000009650339,0.000022552442,0.000012750942,0.0005916871],"genre_scores_gemma":[0.0010863027,0.9976132,0.0004875701,0.00028793505,0.00012107527,0.000017382534,0.000048090467,0.0000027283952,0.00033576562],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993961,0.0001509309,0.00006557049,0.00007897183,0.0002446649,0.00006377446],"domain_scores_gemma":[0.9988475,0.00069759117,0.00010795048,0.000044847675,0.00024576247,0.000056350596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019418068,0.0009279386,0.0020440824,0.0029989006,0.00038112784,0.001809552,0.0013377813,0.0017411653,0.0032003422],"category_scores_gemma":[0.0019477959,0.00051694864,0.0012204231,0.0025366514,0.00073045434,0.00213241,0.0012023505,0.0027272864,0.0017820946],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010505347,0.00008963771,0.00024802174,0.03197618,0.00028666866,0.00025207075,0.000092245995,0.0010261287,0.0030454886,0.014786733,0.03342634,0.91466546],"study_design_scores_gemma":[0.000026101001,0.0001592557,0.0004853133,0.0034808307,0.00017839689,0.00072169723,0.000049650884,0.00034471694,0.0015598475,0.0042652334,0.98869145,0.000037455047],"about_ca_topic_score_codex":0.0011909476,"about_ca_topic_score_gemma":0.0016327337,"teacher_disagreement_score":0.0032003422,"about_ca_system_score_codex":0.0011646998,"about_ca_system_score_gemma":0.0015357696,"threshold_uncertainty_score":0.010706246},"labels":[],"label_agreement":null},{"id":"W3154559926","doi":"10.1186/s13045-021-01071-9","title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cilag; Jazz Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Karyopharm Therapeutics; Gilead Sciences; Bristol-Myers Squibb; Spectrum Pharmaceuticals; Amgen","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Peripheral neuropathy; Adverse effect; Lenalidomide; Proteasome inhibitor; Thalidomide; Hematology; Oncology; Gastroenterology; Surgery; Endocrinology","score_opus":0.025295061423108424,"score_gpt":0.3534062134124607,"score_spread":0.32811115198935226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154559926","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971206,0.0020481076,0.00009464814,0.000075952696,0.00007811634,0.00013207458,0.00007303756,0.000009720321,0.00036775268],"genre_scores_gemma":[0.998276,0.00072623027,0.00018505217,0.00012004034,0.000067317975,0.00011444939,0.00009421382,0.000002239556,0.0004143233],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992187,0.0003956779,0.00008220122,0.00011604365,0.000095308,0.000092036695],"domain_scores_gemma":[0.9990596,0.00029346018,0.00021120258,0.000058409933,0.000032473396,0.0003448772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012972233,0.0004599221,0.001261667,0.0002937798,0.00026213282,0.000543341,0.0003927761,0.0006269242,0.002154408],"category_scores_gemma":[0.0009664941,0.00033173183,0.0010606191,0.00022857031,0.00047200805,0.00057572074,0.00034890647,0.0011661324,0.00020643625],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87512034,0.030192697,0.011883907,0.00035844388,0.00195626,0.00009375123,0.00007373939,0.0011662206,0.016115637,0.00011517585,0.0004020147,0.06252179],"study_design_scores_gemma":[0.15006101,0.80563134,0.03538355,0.00007796658,0.00096769223,0.00015322845,0.00005772607,0.0012797181,0.00462679,0.00014082357,0.0015943954,0.000025820684],"about_ca_topic_score_codex":0.00037471508,"about_ca_topic_score_gemma":0.0014370627,"teacher_disagreement_score":0.002154408,"about_ca_system_score_codex":0.0003950986,"about_ca_system_score_gemma":0.00048733217,"threshold_uncertainty_score":0.007207215},"labels":[],"label_agreement":null},{"id":"W3174383320","doi":"10.1186/s13045-021-01116-z","title":"Molecular pathogenesis of the myeloproliferative neoplasms","year":2021,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Research Board; Canadian Institute for Theoretical Astrophysics; Health Service Executive; Wellcome Trust; Wellcome","keywords":"Epigenetics; Disease; Biology; Myeloid; Myeloproliferative Disorders; Genetics; Bioinformatics; Cancer research; Medicine; Immunology; Gene; Internal medicine","score_opus":0.04123789998553555,"score_gpt":0.3755260178493881,"score_spread":0.33428811786385254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174383320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027215056,0.99765104,0.00014569268,0.00030329736,0.00018660964,0.000004214346,0.000019777548,0.000009418003,0.00140795],"genre_scores_gemma":[0.0016574811,0.99706525,0.00019250518,0.00017142549,0.00018096957,0.0000050712993,0.00003877833,0.0000013063333,0.0006871723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999052,0.000015909729,0.000014934724,0.00001611398,0.000035810008,0.00001202917],"domain_scores_gemma":[0.9998733,0.000050948365,0.000021599533,0.0000042050206,0.000037560665,0.0000124431635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002272697,0.0005405745,0.00071185996,0.0013422418,0.00022345835,0.0007260501,0.000480145,0.0006855809,0.0026287632],"category_scores_gemma":[0.00038924653,0.00014516797,0.00024741964,0.0010122374,0.00029865836,0.0007290599,0.00041834163,0.0010508603,0.0013613915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007448268,0.000054651373,0.00034127317,0.012312232,0.00006441527,0.00066368846,0.00009299163,0.00049654173,0.004446748,0.005913282,0.029160518,0.94637924],"study_design_scores_gemma":[0.000009623994,0.00006164271,0.0011671997,0.0031599952,0.00007124059,0.0054449025,0.000058368325,0.000096077485,0.00087545277,0.002695785,0.9863462,0.000013521867],"about_ca_topic_score_codex":0.0005735499,"about_ca_topic_score_gemma":0.0007953502,"teacher_disagreement_score":0.0026287632,"about_ca_system_score_codex":0.00050487515,"about_ca_system_score_gemma":0.0007917341,"threshold_uncertainty_score":0.008794129},"labels":[],"label_agreement":null},{"id":"W3178156199","doi":"10.1186/s13045-021-01122-1","title":"Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study","year":2021,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Regimen; Population; Lymphoma; Surgery; Gastroenterology; Hematology","score_opus":0.017846038838583666,"score_gpt":0.2586539734881255,"score_spread":0.24080793464954187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178156199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991048,0.00033103017,0.0000308263,0.000032433112,0.0000075412013,0.000011644495,0.00026727887,0.000002114929,0.00021238728],"genre_scores_gemma":[0.9985031,0.00015873465,0.00004496319,0.00006911099,0.000020076497,0.000019762865,0.0010424126,0.0000013538956,0.0001404566],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996877,0.00012209463,0.00003067315,0.000063181076,0.000050563714,0.00004597218],"domain_scores_gemma":[0.99959916,0.00007305339,0.0001199362,0.000044294964,0.000037641978,0.00012580298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007634203,0.00024506648,0.0005931072,0.00032526307,0.00024303418,0.0006351053,0.00023229135,0.0003438429,0.0005237505],"category_scores_gemma":[0.0007556231,0.00017778973,0.0010261295,0.0003183484,0.00023157864,0.00038889417,0.00040544584,0.00055209093,0.00015224352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031772267,0.0010487941,0.94436455,0.00012312416,0.001343345,0.00038487132,0.00026301556,0.00084310264,0.005179178,0.00008017651,0.0007509728,0.013846689],"study_design_scores_gemma":[0.0024966593,0.009500189,0.9834684,0.00002767808,0.000608275,0.0005091984,0.00021462287,0.0010290223,0.00045596182,0.000073782314,0.0015925457,0.000023610575],"about_ca_topic_score_codex":0.0011582379,"about_ca_topic_score_gemma":0.0020322662,"teacher_disagreement_score":0.0011582379,"about_ca_system_score_codex":0.00039091826,"about_ca_system_score_gemma":0.00029121424,"threshold_uncertainty_score":0.00403738},"labels":[],"label_agreement":null},{"id":"W3197223132","doi":"10.1186/s13045-021-01144-9","title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Oncology; Confidence interval; Surgery","score_opus":0.07529656742620855,"score_gpt":0.4012486531152399,"score_spread":0.32595208568903133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197223132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97057706,0.008646814,0.012719349,0.0003076138,0.00033688152,0.002569799,0.0018581996,0.00013356714,0.0028507558],"genre_scores_gemma":[0.9929103,0.00045856956,0.0041728,0.000161417,0.000062171945,0.0013090918,0.00055713445,0.0000137940615,0.00035468102],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9819067,0.01456074,0.0009248659,0.0011551302,0.0011111798,0.00034134745],"domain_scores_gemma":[0.9831808,0.011350202,0.0034643176,0.0011898353,0.0005057096,0.00030911242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017303776,0.0011569776,0.0021900816,0.00089310214,0.00023935779,0.00076485047,0.0009724286,0.0006226467,0.004908989],"category_scores_gemma":[0.025701718,0.00032267114,0.0047622165,0.00074551336,0.0006765128,0.00072477676,0.000990415,0.0015259135,0.00026288294],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7601354,0.0020877274,0.035262816,0.0049754474,0.07105759,0.00009562168,0.00030462706,0.010212207,0.0024410672,0.0023348671,0.0013268827,0.109765664],"study_design_scores_gemma":[0.2875185,0.33521515,0.16147791,0.0011845736,0.116055496,0.00061224157,0.0004926523,0.053926606,0.01506913,0.015925184,0.012209749,0.00031270745],"about_ca_topic_score_codex":0.0006250675,"about_ca_topic_score_gemma":0.0007383821,"teacher_disagreement_score":0.017303776,"about_ca_system_score_codex":0.0008982359,"about_ca_system_score_gemma":0.00094428164,"threshold_uncertainty_score":0.0915122},"labels":[],"label_agreement":null},{"id":"W3209835908","doi":"10.1186/s13045-021-01202-2","title":"Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":574,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; York University","funders":"Shahid Beheshti University of Medical Sciences; Institute for Health Metrics and Evaluation","keywords":"Burden of disease; Anemia; Medicine; Disease; Environmental health; Hematology; Disease burden; Internal medicine","score_opus":0.02272164618525887,"score_gpt":0.3320074399437873,"score_spread":0.30928579375852844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209835908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77219445,0.012980925,0.0006124525,0.0019775631,0.000115252755,0.00012230812,0.20722915,0.00008153819,0.004686305],"genre_scores_gemma":[0.9158444,0.0045383563,0.0005764823,0.00037070614,0.000050139246,0.00012740339,0.07763002,0.000013986034,0.00084854267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996494,0.00009330613,0.00005860952,0.000044455977,0.00007900971,0.00007517835],"domain_scores_gemma":[0.9993843,0.000055495664,0.000296295,0.000028415538,0.00016680619,0.00006874092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094554474,0.00031362602,0.0003370958,0.0011831322,0.00024376615,0.0005567035,0.00033161958,0.00028073243,0.0010169409],"category_scores_gemma":[0.0014289015,0.0001880499,0.0012996473,0.002537332,0.00015450091,0.00038786046,0.0007335246,0.0005528495,0.00036587054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017187362,0.000020597872,0.9803288,0.00041061584,0.00067100045,0.00013022068,0.00035218635,0.00058123417,0.00019195769,0.00009668969,0.009123662,0.007921088],"study_design_scores_gemma":[0.000007663376,0.000017564842,0.99619883,0.000092011076,0.00012184838,0.00010640442,0.00028263053,0.00016658149,0.000040914252,0.000022842205,0.0029362577,0.000006445189],"about_ca_topic_score_codex":0.118849814,"about_ca_topic_score_gemma":0.11814829,"teacher_disagreement_score":0.118849814,"about_ca_system_score_codex":0.0010367567,"about_ca_system_score_gemma":0.0009438009,"threshold_uncertainty_score":0.23631608},"labels":[],"label_agreement":null},{"id":"W4214875473","doi":"10.1186/s13045-022-01235-1","title":"The long and short non-coding RNAs modulating EZH2 signaling in cancer","year":2022,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Cancer Science Institute of Singapore, National University of Singapore; Ministry of Education, India; Terry Fox Research Institute; National Research Foundation; Ministry of Education - Singapore; National Research Foundation Singapore; National University of Singapore; Cancer Research UK","keywords":"Hematology; EZH2; Internal medicine; Coding (social sciences); Cancer; Medicine; Long non-coding RNA; Cancer research; Oncology; Biology; Computational biology; Bioinformatics; Genetics; RNA; Histone; DNA; Gene; Mathematics","score_opus":0.05187591141921844,"score_gpt":0.40656639184297055,"score_spread":0.3546904804237521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214875473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033284524,0.9923298,0.0006674488,0.0007185608,0.00043552584,0.000009686755,0.000056671066,0.000023358029,0.0024305377],"genre_scores_gemma":[0.020456862,0.9756674,0.00060279755,0.00047505417,0.00049536256,0.000018545474,0.00014788272,0.0000038225917,0.0021323555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999299,0.0000111365,0.000010746331,0.000010070694,0.000025737812,0.0000124437265],"domain_scores_gemma":[0.99995124,0.000013809441,0.000010406679,0.0000015475305,0.000014131206,0.000008798633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017079264,0.0002981713,0.0003697447,0.00043464004,0.00013339928,0.0003566417,0.00026046816,0.00036997424,0.0014321029],"category_scores_gemma":[0.00018911473,0.0000877649,0.00020160685,0.0004407008,0.00015325725,0.00047729188,0.0002561661,0.00048113003,0.0004549302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028882394,0.000074824195,0.0013922583,0.015589729,0.00017449936,0.0009220761,0.00016226365,0.00075091515,0.07984535,0.0071730427,0.035396576,0.8582296],"study_design_scores_gemma":[0.00004587593,0.0003188584,0.0064879404,0.00091950357,0.00021670846,0.0028374721,0.00011218438,0.0004172608,0.024924967,0.002978507,0.960705,0.00003563698],"about_ca_topic_score_codex":0.00032007453,"about_ca_topic_score_gemma":0.00086040824,"teacher_disagreement_score":0.0014321029,"about_ca_system_score_codex":0.0003117637,"about_ca_system_score_gemma":0.00044636006,"threshold_uncertainty_score":0.0047908425},"labels":[],"label_agreement":null},{"id":"W4225292988","doi":"10.1186/s13045-022-01268-6","title":"Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena","year":2022,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Canadian Cancer Society; Foundation for the National Institutes of Health","keywords":"Prostate cancer; Medicine; Prostate; Magnetic resonance imaging; Visibility; Radiology; Cancer; Pathology; Internal medicine","score_opus":0.01817164259771498,"score_gpt":0.31568404235698816,"score_spread":0.2975123997592732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225292988","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034806877,0.0074054757,0.0018133643,0.92488605,0.01128141,0.0000611976,0.00014041334,0.00022093933,0.019384278],"genre_scores_gemma":[0.35241395,0.009130499,0.002446007,0.5603678,0.050621506,0.00008372969,0.00015787286,0.00008371045,0.02469495],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.999121,0.00032870256,0.00009106169,0.00010717345,0.00026619475,0.00008575046],"domain_scores_gemma":[0.9969656,0.0016925927,0.00023546565,0.00021026442,0.00062472007,0.0002714593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089980644,0.0002017505,0.00043183914,0.00025821707,0.00082436,0.0010487614,0.00029410011,0.0036415618,0.0018826704],"category_scores_gemma":[0.006695958,0.00017300982,0.00025606502,0.00023743416,0.00086669874,0.00062440836,0.00024782028,0.0042497455,0.0021201265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038269666,0.00010967193,0.033183564,0.0001972749,0.0000638767,0.050109774,0.0005271944,0.00016979454,0.006829522,0.0058945506,0.8055637,0.09696835],"study_design_scores_gemma":[0.00012423226,0.00035973723,0.022413747,0.0002794132,0.00008079092,0.15796,0.0011314416,0.0023401896,0.005630431,0.013347435,0.79625666,0.0000758506],"about_ca_topic_score_codex":0.00082901,"about_ca_topic_score_gemma":0.0013691304,"teacher_disagreement_score":0.0036415618,"about_ca_system_score_codex":0.0009702033,"about_ca_system_score_gemma":0.00042895062,"threshold_uncertainty_score":0.0070393085},"labels":[],"label_agreement":null},{"id":"W4229027500","doi":"10.1186/s13045-022-01276-6","title":"Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer","year":2022,"lang":"en","type":"erratum","venue":"Journal of Hematology & Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hematology; EZH2; Coding (social sciences); Long non-coding RNA; Computational biology; Cancer; Internal medicine; Correct name; Cancer research; Medicine; Bioinformatics; Oncology; Biology; Genetics; RNA; Histone; DNA; Mathematics; Gene; Statistics","score_opus":0.01855452138919512,"score_gpt":0.33637528792193194,"score_spread":0.31782076653273683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229027500","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013353443,0.0011794553,0.00070629676,0.043794833,0.9497155,0.000022668866,0.0010364251,0.00036667922,0.003044679],"genre_scores_gemma":[0.014022623,0.011191408,0.007375864,0.09372302,0.50661415,0.00026989685,0.0038141313,0.0021461989,0.36084273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704427,0.000398572,0.00049017527,0.00034933546,0.0014723816,0.00024527154],"domain_scores_gemma":[0.9809059,0.004538576,0.00090885255,0.0011582754,0.011258771,0.001229708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032633492,0.0019205175,0.001489172,0.0025767696,0.0021514578,0.0030782935,0.0028035175,0.00539771,0.066484645],"category_scores_gemma":[0.03956231,0.00089339924,0.0015706477,0.0014928805,0.0017375008,0.0017711603,0.0015606387,0.009658187,0.038968142],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032856035,0.000004098051,0.000056257646,0.000106070795,0.000010312594,0.00027655278,0.000012738981,0.000037377085,0.000069929425,0.0004441495,0.9928945,0.0060550803],"study_design_scores_gemma":[0.00005618514,0.000016400327,0.0005992064,0.00030088183,0.00004047995,0.0012349143,0.000042874042,0.00020759885,0.0004658718,0.00119648,0.99580824,0.000030770156],"about_ca_topic_score_codex":0.009857356,"about_ca_topic_score_gemma":0.013146142,"teacher_disagreement_score":0.066484645,"about_ca_system_score_codex":0.0029426056,"about_ca_system_score_gemma":0.0040298034,"threshold_uncertainty_score":0.2224133},"labels":[],"label_agreement":null},{"id":"W4281263643","doi":"10.1186/s13045-022-01289-1","title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","year":2022,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Internal medicine; Low molecular weight heparin; Relative risk; Heparin; Cancer; Hematology; Major bleeding; Intensive care medicine; Confidence interval","score_opus":0.11199116437394019,"score_gpt":0.4325701751751657,"score_spread":0.32057901080122553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281263643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008058462,0.99823207,0.00016034335,0.00016522587,0.00010374694,0.00012288465,0.00024786667,0.000008082705,0.00015396455],"genre_scores_gemma":[0.023394395,0.97398067,0.0008686297,0.0006584781,0.00018729811,0.00032542052,0.0003947319,0.0000117272275,0.00017868308],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99462503,0.0024125802,0.0016237425,0.0004478273,0.000720687,0.00017007369],"domain_scores_gemma":[0.98932004,0.0076872017,0.001757804,0.00019553686,0.000911894,0.00012746442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00938341,0.0020646506,0.012513775,0.004683556,0.00038458197,0.0021165009,0.0013196416,0.0015777391,0.004912846],"category_scores_gemma":[0.02137383,0.000930579,0.017901761,0.005434951,0.00044541285,0.0012784048,0.0009833561,0.0015211492,0.00035019763],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015673753,0.000027147402,0.0014900974,0.73544896,0.2144939,0.00009395676,0.00006098515,0.00035187363,0.00023988672,0.0002475596,0.0024283668,0.043549832],"study_design_scores_gemma":[0.0012387916,0.00024782532,0.00326005,0.10613095,0.8799929,0.00014612201,0.000043208747,0.00021078486,0.00017458136,0.0004014487,0.0081239855,0.000029353028],"about_ca_topic_score_codex":0.005766334,"about_ca_topic_score_gemma":0.014618261,"teacher_disagreement_score":0.012513775,"about_ca_system_score_codex":0.0021420636,"about_ca_system_score_gemma":0.0038656162,"threshold_uncertainty_score":0.0496248},"labels":[],"label_agreement":null},{"id":"W4293125198","doi":"10.1186/s13045-022-01333-0","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thrombosis; Hematology; Internal medicine; Chronic lymphocytic leukemia; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Disease; Intensive care medicine; Pediatrics; Leukemia; Infectious disease (medical specialty)","score_opus":0.08628222026284342,"score_gpt":0.39319395771899157,"score_spread":0.30691173745614814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293125198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819595,0.0008645068,0.000054376127,0.000049170205,0.0000040369214,0.00002660656,0.0004247244,0.0000017512949,0.00037892602],"genre_scores_gemma":[0.99830794,0.00045818413,0.00009936005,0.00013925025,0.000025880021,0.00004107328,0.00080177275,0.000002299229,0.00012420185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984316,0.0005572315,0.00022779034,0.0003164601,0.00019700397,0.00026987822],"domain_scores_gemma":[0.9969824,0.0005124891,0.0014557121,0.00018548651,0.00039651257,0.00046747475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023333004,0.00043301398,0.00064588035,0.0015821763,0.00078689883,0.0011078496,0.00046295737,0.00078578724,0.0013719146],"category_scores_gemma":[0.0036717241,0.000335726,0.00054767943,0.0024487507,0.0004219981,0.0008594852,0.0010076497,0.00039593736,0.0002739248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015252556,0.00003507897,0.9987602,0.000018703075,0.000035559147,0.00012601727,0.00013040256,0.000010433235,0.000044149492,0.000012730583,0.000097848715,0.00057624857],"study_design_scores_gemma":[0.000042718275,0.00025359064,0.997355,0.000047328806,0.00005561257,0.00078248756,0.00077707076,0.00004234976,0.000027691238,0.000014740334,0.0005955546,0.0000059084355],"about_ca_topic_score_codex":0.005344437,"about_ca_topic_score_gemma":0.0047069425,"teacher_disagreement_score":0.005344437,"about_ca_system_score_codex":0.000693019,"about_ca_system_score_gemma":0.00085542904,"threshold_uncertainty_score":0.01233983},"labels":[],"label_agreement":null},{"id":"W4323311378","doi":"10.1186/s13045-023-01417-5","title":"Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Meta-analysis; Hematology; Myeloid leukemia; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Intensive care medicine; Cancer","score_opus":0.13974557173687224,"score_gpt":0.455098530342097,"score_spread":0.3153529586052248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323311378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00564302,0.9926125,0.00035444967,0.00016949308,0.00008822214,0.00017819357,0.0007063987,0.000018627594,0.00022908738],"genre_scores_gemma":[0.1724373,0.82302904,0.0015134246,0.000700412,0.00017664144,0.00079592766,0.0010981832,0.000023142511,0.00022595284],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935634,0.0030377472,0.0018145748,0.0007218138,0.0006249653,0.00023747579],"domain_scores_gemma":[0.9850986,0.01074497,0.0024982125,0.00036587688,0.0010839385,0.00020838031],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009382679,0.0022046524,0.015924718,0.0067445296,0.0005288432,0.0025829757,0.001912249,0.001638297,0.0030501077],"category_scores_gemma":[0.022482777,0.0012107637,0.032206584,0.008092624,0.00054216327,0.0014352062,0.0012308992,0.0014477059,0.00023547324],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013941267,0.000027024598,0.0045063365,0.42758033,0.55339843,0.00013385747,0.00007903061,0.0007509189,0.00019358854,0.0001321473,0.00077156,0.011032616],"study_design_scores_gemma":[0.00043143035,0.00015524503,0.004078813,0.026572749,0.9667012,0.00009944459,0.000044397035,0.00021469075,0.00009296362,0.00015162131,0.001435432,0.000022071426],"about_ca_topic_score_codex":0.0075087687,"about_ca_topic_score_gemma":0.016190698,"teacher_disagreement_score":0.9840753,"about_ca_system_score_codex":0.0026593339,"about_ca_system_score_gemma":0.003143822,"threshold_uncertainty_score":0.049620926},"labels":[],"label_agreement":null},{"id":"W4364381091","doi":"10.1186/s13045-023-01431-7","title":"Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study","year":2023,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Medical College of Wisconsin; StemCyte; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Incyte; Pfizer; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; AstraZeneca; Bristol-Myers Squibb; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Hematopoietic cell; Hematology; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Haematopoiesis; Genetics; Biology; Stem cell; Transplantation; Bone marrow","score_opus":0.029290541222779326,"score_gpt":0.30702762840655023,"score_spread":0.2777370871837709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364381091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874973,0.00013496519,0.00020209303,0.00004323342,0.0000044447306,0.000016334361,0.00070237374,0.000008807585,0.00013799104],"genre_scores_gemma":[0.99597317,0.00009469939,0.00040574142,0.0000787561,0.000019374884,0.000023408915,0.0031528375,0.000013283147,0.00023880713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995333,0.000092440816,0.000032012933,0.00019749258,0.000071586095,0.000073173585],"domain_scores_gemma":[0.9993154,0.00017460858,0.00012466984,0.000114740214,0.0000848632,0.00018574351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009804519,0.00042979518,0.0005815019,0.0010805195,0.0004952099,0.0008482574,0.0005544339,0.0005836742,0.0020932388],"category_scores_gemma":[0.0017999405,0.00027335293,0.00084976247,0.0008889193,0.00031614534,0.00021741794,0.00060880923,0.0007028426,0.0004562311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001988473,0.00042511558,0.96233356,0.00008304856,0.0008161226,0.0011428816,0.00035677772,0.00076731184,0.014425148,0.00014486579,0.0014005393,0.016116189],"study_design_scores_gemma":[0.00011168564,0.00033128023,0.9948868,0.000011730888,0.00027547064,0.0010184981,0.00016993588,0.0016338031,0.0005128307,0.00006512255,0.00096853514,0.000014332318],"about_ca_topic_score_codex":0.0023856563,"about_ca_topic_score_gemma":0.0026028943,"teacher_disagreement_score":0.0023856563,"about_ca_system_score_codex":0.00030057048,"about_ca_system_score_gemma":0.00045005014,"threshold_uncertainty_score":0.0070025325},"labels":[],"label_agreement":null},{"id":"W4389831827","doi":"10.1186/s13045-023-01520-7","title":"Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"National Cancer Institute","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Cohort; Retrospective cohort study; Hematology; Hematopoietic stem cell transplantation; Transplantation; Lymphoma","score_opus":0.032297133307245776,"score_gpt":0.3348060902558893,"score_spread":0.30250895694864355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389831827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909733,0.0018731487,0.0050427257,0.00040544197,0.000014405481,0.000056939094,0.0005226879,0.00006475111,0.0010466238],"genre_scores_gemma":[0.99629754,0.0004783536,0.0022450516,0.00003861077,0.000024343357,0.000021207337,0.0008212386,0.000011654446,0.00006210777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917287,0.00034377744,0.00006784431,0.00014747464,0.00019064662,0.00007726805],"domain_scores_gemma":[0.99521905,0.0022950724,0.0006667109,0.0005711468,0.0009946416,0.00025333997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006190217,0.00071855925,0.00048542366,0.0016370759,0.00042657752,0.0012154568,0.0005501476,0.00027108844,0.0004272796],"category_scores_gemma":[0.008660248,0.0001620268,0.0006856351,0.0016290118,0.0004947909,0.0006678575,0.0009826289,0.00072852377,0.00012110955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015703973,0.000050470586,0.96399033,0.000036317324,0.00017739151,0.00016166184,0.00023545063,0.0014600465,0.0006063212,0.00009343348,0.0006493553,0.032382242],"study_design_scores_gemma":[0.00003396841,0.00028671089,0.96806705,0.0000561754,0.0004905368,0.0013798387,0.00066320895,0.024643319,0.0009465344,0.0007050434,0.0026896517,0.000037849644],"about_ca_topic_score_codex":0.005280968,"about_ca_topic_score_gemma":0.005789741,"teacher_disagreement_score":0.006190217,"about_ca_system_score_codex":0.0007219934,"about_ca_system_score_gemma":0.0011663501,"threshold_uncertainty_score":0.032737374},"labels":[],"label_agreement":null},{"id":"W4393397203","doi":"10.1186/s13045-024-01535-8","title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National University Health System; National Natural Science Foundation of China","keywords":"Tumor microenvironment; Immunotherapy; Immune system; Cancer immunotherapy; Cancer research; Medicine; Nanocarriers; Cancer cell; Cancer; Immunology; Pharmacology; Internal medicine","score_opus":0.010035341975949318,"score_gpt":0.26504064326531873,"score_spread":0.25500530128936943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393397203","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015544982,0.94732904,0.014486407,0.00432269,0.0013002688,0.00004030154,0.000045662313,0.00012959678,0.016801031],"genre_scores_gemma":[0.22469485,0.74210006,0.0120580625,0.0028135325,0.0013082788,0.00009461616,0.00009232078,0.000050920185,0.016787333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987066,0.000038927996,0.0000074343857,0.000023440243,0.00003755398,0.000021966312],"domain_scores_gemma":[0.999931,0.000029464629,0.0000126277,0.000003766009,0.000012592993,0.000010506878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030788247,0.00029372855,0.00038458453,0.00037318445,0.00025482124,0.00065092195,0.00028667937,0.0010170145,0.001241367],"category_scores_gemma":[0.00016644491,0.000143808,0.00020608363,0.00023602934,0.0005526169,0.00084053894,0.0005304696,0.0008462935,0.0005345581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018746452,0.00017937411,0.0006730838,0.004803737,0.00006732613,0.0010922208,0.0003691225,0.0048048096,0.2883007,0.11526336,0.023012778,0.56124604],"study_design_scores_gemma":[0.000031529475,0.0004533264,0.0010245753,0.00067682867,0.000051314477,0.0019821273,0.00023565702,0.004351771,0.1172104,0.03307581,0.84086317,0.000043494787],"about_ca_topic_score_codex":0.00030837837,"about_ca_topic_score_gemma":0.0005385066,"teacher_disagreement_score":0.001241367,"about_ca_system_score_codex":0.0005066603,"about_ca_system_score_gemma":0.00041009547,"threshold_uncertainty_score":0.004152775},"labels":[],"label_agreement":null},{"id":"W4395007321","doi":"10.1186/s13045-024-01542-9","title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; TG Therapeutics; National Cancer Institute; Laffey-McHugh Foundation; Pharmacyclics; Genentech; Celgene; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; University of Pennsylvania; Gilead Sciences; Leukemia and Lymphoma Society","keywords":"Bendamustine; Medicine; Cytokine release syndrome; Internal medicine; Fludarabine; Cyclophosphamide; Gastroenterology; Lymphoma; Immunotherapy; Rituximab; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03244576333228277,"score_gpt":0.3624544389628308,"score_spread":0.33000867563054803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395007321","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829274,0.00070520595,0.00016072605,0.000030494557,0.0000050520684,0.000034823384,0.00007403216,0.000008203663,0.0006886533],"genre_scores_gemma":[0.9990676,0.00020183373,0.00012195096,0.000033636417,0.000010512173,0.00003088353,0.0002619768,0.000002919966,0.00026865044],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976665,0.000092496266,0.000012711332,0.00003689613,0.00005166972,0.000039459763],"domain_scores_gemma":[0.99968123,0.00010805048,0.000086325956,0.000022227458,0.000016262744,0.00008599735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000390398,0.00018403586,0.00042171218,0.00016670252,0.00015483022,0.00033222116,0.000180641,0.00018531848,0.0009456159],"category_scores_gemma":[0.00059298764,0.000111097004,0.00027415,0.00012063468,0.00018343444,0.0002481681,0.00014852331,0.00051814364,0.00028765926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17603816,0.012135289,0.18651634,0.00029225516,0.00034752063,0.0014159835,0.00049291283,0.0031924993,0.3255162,0.00031470007,0.0013392705,0.2923989],"study_design_scores_gemma":[0.0089041125,0.314194,0.5808529,0.00007958192,0.00039873848,0.004605238,0.00021883819,0.0041930047,0.07609816,0.00019053931,0.010219179,0.0000457157],"about_ca_topic_score_codex":0.00044400647,"about_ca_topic_score_gemma":0.00068795343,"teacher_disagreement_score":0.0009456159,"about_ca_system_score_codex":0.0003746827,"about_ca_system_score_gemma":0.000310337,"threshold_uncertainty_score":0.003163457},"labels":[],"label_agreement":null},{"id":"W4396904518","doi":"10.1186/s13045-024-01541-w","title":"Critical role of the gut microbiota in immune responses and cancer immunotherapy","year":2024,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Natural Science Foundation of China; National Science Foundation","keywords":"Hematology; Immunotherapy; Immune system; Cancer; Cancer immunotherapy; Medicine; Gut flora; Immunology; Internal medicine; Oncology","score_opus":0.020512318260275622,"score_gpt":0.40514961243919795,"score_spread":0.38463729417892234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017046242,0.997526,0.0001874325,0.0008173527,0.0003626052,0.000003244398,0.000013684995,0.000006776799,0.00091257144],"genre_scores_gemma":[0.0015387187,0.99680847,0.00022951934,0.00039456482,0.000320137,0.0000056052313,0.00002365325,0.0000015811609,0.0006777158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997614,0.00006463044,0.000025722999,0.00002899112,0.00008716031,0.000032119027],"domain_scores_gemma":[0.99968886,0.00014981879,0.000033247168,0.000008870592,0.00008246901,0.00003672693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057705125,0.0005533532,0.0008629218,0.0012360681,0.00029836778,0.0011396707,0.00049806613,0.0012831264,0.0030760306],"category_scores_gemma":[0.0008543785,0.00016336842,0.0004605905,0.0008934759,0.00044769552,0.0010103047,0.00072335324,0.0020421292,0.001232422],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102304526,0.00006574727,0.00034139812,0.010595736,0.00010027872,0.00028041963,0.00008259407,0.00035142998,0.0029357823,0.009828534,0.03422345,0.9410923],"study_design_scores_gemma":[0.000016039514,0.00009590332,0.0011282318,0.0037147296,0.000092231334,0.0012247227,0.00007690359,0.00011974341,0.0008476132,0.004387691,0.9882796,0.000016473174],"about_ca_topic_score_codex":0.0007985603,"about_ca_topic_score_gemma":0.0013037738,"teacher_disagreement_score":0.0030760306,"about_ca_system_score_codex":0.0006433045,"about_ca_system_score_gemma":0.0014190227,"threshold_uncertainty_score":0.010290325},"labels":[],"label_agreement":null},{"id":"W4399775192","doi":"10.1186/s13045-024-01565-2","title":"Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Prospective cohort study; Esophageal cancer; Multiplex; Cell-free fetal DNA; Cancer; Receiver operating characteristic; Stage (stratigraphy); Oncology; Bioinformatics; Prenatal diagnosis; Biology","score_opus":0.03270343736734796,"score_gpt":0.36867562552479805,"score_spread":0.3359721881574501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399775192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984674,0.00016856598,0.0009892375,0.000010923675,0.000008739333,0.00016684191,0.00009691708,0.000006545095,0.00008491533],"genre_scores_gemma":[0.99837023,0.00005743308,0.0010246226,0.00004641267,0.00002084636,0.0001377953,0.00025512365,0.0000029688288,0.000084562336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729055,0.0009288834,0.00023197847,0.000991733,0.0004314694,0.00012540942],"domain_scores_gemma":[0.99645907,0.0006477113,0.0010474384,0.00073729106,0.0006896311,0.00041877196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045871898,0.0011953396,0.00076039735,0.0004590116,0.00049869035,0.00069371326,0.00043991697,0.0008337366,0.00048644128],"category_scores_gemma":[0.0042563044,0.00066691963,0.00047751644,0.00030845628,0.00089290144,0.000499646,0.00063851045,0.0005701043,0.00018573881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012171833,0.0014479415,0.9570206,0.00013398084,0.000622917,0.00016596845,0.00056732877,0.00020835082,0.018936025,0.000043845597,0.00014911093,0.008532104],"study_design_scores_gemma":[0.0020509067,0.027531065,0.95200604,0.000027343425,0.001164313,0.0018105387,0.0003935494,0.0025143889,0.011261183,0.00007397003,0.0010978446,0.000068823945],"about_ca_topic_score_codex":0.000610661,"about_ca_topic_score_gemma":0.0007180917,"teacher_disagreement_score":0.0045871898,"about_ca_system_score_codex":0.0003944959,"about_ca_system_score_gemma":0.0005054939,"threshold_uncertainty_score":0.024259686},"labels":[],"label_agreement":null},{"id":"W4405659313","doi":"10.1186/s13045-024-01653-3","title":"Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study","year":2024,"lang":"en","type":"erratum","venue":"Journal of Hematology & Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Hematology; Esophageal cancer; Medicine; Internal medicine; Oncology; DNA methylation; Double blinded; Multicenter study; Methylation; Prospective cohort study; Cancer; Pathology; Cancer research; DNA; Biology; Randomized controlled trial; Alternative medicine; Biochemistry; Gene","score_opus":0.0269657228408138,"score_gpt":0.3683365384295238,"score_spread":0.34137081558871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405659313","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009156951,0.001192536,0.0012576726,0.06063505,0.93259126,0.00007452103,0.0020058642,0.0002849323,0.0010424885],"genre_scores_gemma":[0.08624873,0.009301614,0.015488754,0.21831453,0.53642464,0.0007721236,0.0055390657,0.0023842934,0.12552625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654645,0.0008879867,0.00079287385,0.0005747318,0.0009164978,0.00028145208],"domain_scores_gemma":[0.97411376,0.008944888,0.0018869084,0.0021172545,0.011689853,0.0012473011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061748913,0.0016871989,0.0017967401,0.0015036223,0.0012757484,0.0017090124,0.002342847,0.0049124956,0.022592528],"category_scores_gemma":[0.074902825,0.00084763806,0.0013997956,0.0009952807,0.0013205694,0.001035993,0.00082248275,0.0061828587,0.010264537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043201697,0.000025317588,0.0008717379,0.00056533294,0.00011193571,0.0012280878,0.00005485549,0.00007912844,0.00020050324,0.0006066135,0.9844663,0.01135827],"study_design_scores_gemma":[0.0011768547,0.00027575812,0.012304542,0.0018295454,0.00070678815,0.007087754,0.00030195602,0.0012438875,0.0030201755,0.0027875176,0.9690571,0.00020805174],"about_ca_topic_score_codex":0.007872869,"about_ca_topic_score_gemma":0.008296089,"teacher_disagreement_score":0.022592528,"about_ca_system_score_codex":0.0021619978,"about_ca_system_score_gemma":0.0031721732,"threshold_uncertainty_score":0.075579464},"labels":[],"label_agreement":null},{"id":"W4406470071","doi":"10.1186/s13045-024-01657-z","title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Foghorn Therapeutics; Celgene; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Refractory (planetary science); Open label; Myeloid leukemia; Azacitidine; Hematology; Internal medicine; Clinical trial","score_opus":0.046883493649556594,"score_gpt":0.38586445423521454,"score_spread":0.33898096058565796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406470071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409324,0.003556397,0.00025573294,0.00024486764,0.000060098115,0.0006829302,0.0003588687,0.000056116838,0.00069188146],"genre_scores_gemma":[0.9943942,0.0020878548,0.0007867118,0.00039770146,0.00021706433,0.00063011295,0.0008362496,0.000018412939,0.00063175947],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993049,0.00041034175,0.00004640303,0.00009727368,0.00005997478,0.000081111364],"domain_scores_gemma":[0.99925274,0.00014989289,0.00018256504,0.00007580035,0.0000478954,0.00029110108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028105967,0.0011278609,0.002185595,0.0004715675,0.0003805027,0.0008775163,0.00071260013,0.00088988285,0.0024172694],"category_scores_gemma":[0.00094013824,0.00048228464,0.0015135874,0.00048443378,0.0005964069,0.0006852627,0.00035984538,0.002070346,0.00044115874],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84853256,0.020693906,0.008052805,0.0010216492,0.0039303955,0.0001954037,0.00021904138,0.001182894,0.026214762,0.000110775705,0.0017213962,0.08812445],"study_design_scores_gemma":[0.71655995,0.2590931,0.017487783,0.00006153683,0.0014585471,0.00033801649,0.000050212537,0.000726198,0.002485797,0.000119757904,0.0015897113,0.00002931884],"about_ca_topic_score_codex":0.00039732025,"about_ca_topic_score_gemma":0.0015241047,"teacher_disagreement_score":0.0028105967,"about_ca_system_score_codex":0.0006258806,"about_ca_system_score_gemma":0.0008154219,"threshold_uncertainty_score":0.0148640275},"labels":[],"label_agreement":null},{"id":"W4406591519","doi":"10.1186/s13045-024-01645-3","title":"Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; National Institutes of Health; California Institute for Regenerative Medicine","keywords":"Oncolytic virus; Immune system; Flow cytometry; Ex vivo; Cancer research; Cytotoxic T cell; Biology; Proteasome inhibitor; Bortezomib; In vivo; Immunology; Multiple myeloma; Medicine; In vitro","score_opus":0.01607445195790872,"score_gpt":0.3285177114576243,"score_spread":0.3124432594997156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406591519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076545,0.004341366,0.001789359,0.00012020292,0.00006651709,0.00006222739,0.00034957886,0.00017976046,0.0023255944],"genre_scores_gemma":[0.9963086,0.0012492177,0.0009937619,0.000037535243,0.000027096949,0.000033204975,0.00029708497,0.000019046603,0.0010343113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998448,0.00002129259,0.000010695626,0.00002519377,0.000049753013,0.00004831116],"domain_scores_gemma":[0.99991405,0.000016812251,0.000026154754,0.0000117548325,0.0000101217665,0.000021090224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016728388,0.0004183518,0.00045858428,0.00023410613,0.00011996774,0.00033468805,0.00018401937,0.00018741729,0.0015724772],"category_scores_gemma":[0.00011719091,0.00009147245,0.00029360398,0.00016585966,0.00017623254,0.00017926506,0.00016042279,0.00076456554,0.00036380262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012093344,0.00040598222,0.00027710453,0.00011801744,0.000025703428,0.000052333224,0.000017313401,0.0003782635,0.9849835,0.0000964392,0.00024567218,0.012190292],"study_design_scores_gemma":[0.00017141638,0.00433523,0.004999426,0.0000106563475,0.000064234686,0.00028565704,0.0000087738945,0.0012119989,0.9853065,0.000052802803,0.0035483479,0.000005002195],"about_ca_topic_score_codex":0.0003173581,"about_ca_topic_score_gemma":0.000689042,"teacher_disagreement_score":0.0015724772,"about_ca_system_score_codex":0.0003225564,"about_ca_system_score_gemma":0.0002491002,"threshold_uncertainty_score":0.005260527},"labels":[],"label_agreement":null},{"id":"W4415516512","doi":"10.1186/s13045-025-01741-y","title":"B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia","year":2025,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"National Cancer Institute; National Institutes of Health; Center for Cancer Research","keywords":"Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Antigen; Leukemia; B cell; Myeloid; Flow cytometry","score_opus":0.02319117376752284,"score_gpt":0.3493004129627951,"score_spread":0.3261092391952723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415516512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707171,0.011875078,0.013088842,0.00042965717,0.00007667089,0.0001388639,0.00015793028,0.00014640232,0.0033693542],"genre_scores_gemma":[0.9918154,0.00251905,0.003619068,0.000121690326,0.000027865728,0.000052329473,0.00016779386,0.000011798653,0.0016649984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999926,0.000017071037,0.000004213841,0.000014893189,0.000021736729,0.000016203556],"domain_scores_gemma":[0.9999721,0.000004460341,0.0000065783865,0.0000032043865,0.00000569269,0.000007910575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010245215,0.000196253,0.00014775728,0.00016286758,0.00011379237,0.0002879987,0.00013593494,0.00023196844,0.0010163481],"category_scores_gemma":[0.00008888534,0.00006332484,0.000101896294,0.00012559834,0.00014256896,0.00016932048,0.00015865164,0.0005129199,0.00029177757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007332582,0.000037394275,0.00047018117,0.00006615307,0.0000051802535,0.000037310387,0.000010101014,0.00021731526,0.99018914,0.0003153017,0.00013640415,0.0084422985],"study_design_scores_gemma":[0.00005105417,0.000841773,0.0047590216,0.000019392433,0.00004120503,0.0007764145,0.000031408537,0.003132717,0.9607541,0.0004649304,0.029122524,0.0000055205846],"about_ca_topic_score_codex":0.00025263868,"about_ca_topic_score_gemma":0.00025570102,"teacher_disagreement_score":0.0010163481,"about_ca_system_score_codex":0.00021485926,"about_ca_system_score_gemma":0.00021228028,"threshold_uncertainty_score":0.0034000278},"labels":[],"label_agreement":null},{"id":"W4416211821","doi":"10.1186/s13045-025-01751-w","title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Hematology; Cohort; IDH1; Myeloid; Mutation; Cohort study","score_opus":0.027824730235924865,"score_gpt":0.3782625102164903,"score_spread":0.35043777998056547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416211821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639482,0.009287439,0.0024739688,0.0011944601,0.00022981492,0.0018792624,0.016687589,0.0001713571,0.004127981],"genre_scores_gemma":[0.9423853,0.004153375,0.0029630172,0.0022826395,0.00032156697,0.001563177,0.04317249,0.000099609104,0.0030589544],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9986816,0.00062550954,0.00006722905,0.00013812052,0.000243105,0.00024441912],"domain_scores_gemma":[0.9979017,0.00032905178,0.00054768164,0.00027606572,0.00026608698,0.0006793966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008295653,0.0011502699,0.0014578294,0.0003398285,0.00040566231,0.0011782836,0.0008375787,0.00070891913,0.0021576807],"category_scores_gemma":[0.002399973,0.00030255574,0.0018880607,0.0004449276,0.000380968,0.0007276436,0.0006827332,0.0018704187,0.0008247847],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6237144,0.015986526,0.09955028,0.0013876447,0.00748121,0.0006524005,0.00056436274,0.0061169486,0.024207247,0.00065967976,0.042204402,0.17747487],"study_design_scores_gemma":[0.29510838,0.2648319,0.36586896,0.00037585932,0.009428577,0.0020528494,0.00030103404,0.004549106,0.0117338905,0.0010874678,0.044477373,0.00018465605],"about_ca_topic_score_codex":0.0010978888,"about_ca_topic_score_gemma":0.0023294894,"teacher_disagreement_score":0.008295653,"about_ca_system_score_codex":0.0010365602,"about_ca_system_score_gemma":0.0015852978,"threshold_uncertainty_score":0.043872118},"labels":[],"label_agreement":null}]}